FACTORS INFLUENCING PLACENTAL TRANSFER OF LOPINAVIR:  BINDING, UPTAKE AND EFFLUX by Gulati, Abhishek
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2009
FACTORS INFLUENCING PLACENTAL
TRANSFER OF LOPINAVIR: BINDING,
UPTAKE AND EFFLUX
Abhishek Gulati
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Pharmacy and Pharmaceutical Sciences Commons
© The Author
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses
and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/1852
School of Pharmacy  
Virginia Commonwealth University  
 
 
 
This is to certify that the thesis prepared by Abhishek Gulati entitled  
FACTORS INFLUENCING PLACENTAL TRANSFER OF LOPINAVIR:  
BINDING, UPTAKE AND EFFLUX  
has been approved by his committee as satisfactory completion of the thesis requirement 
for the degree of Master of Science in Pharmaceutical Sciences 
 
 
 
 
Phillip M. Gerk, Pharm D., Ph.D., School of Pharmacy  
 
 
 
F. Douglas Boudinot, Ph.D., School of Pharmacy 
 
 
 
Scott W. Walsh, Ph.D., School of Medicine 
 
 
 
Douglas H. Sweet, Ph.D., School of Pharmacy 
 
 
 
Peter R. Byron, Ph.D., Chairman of the Department of Pharmaceutics, School of Pharmacy 
 
 
 
Victor A. Yanchick, Ph.D., Dean of the School of Pharmacy 
 
 
 
Dr. F. Douglas Boudinot, Ph.D., Dean of the Graduate School 
 
 
June 29, 2009 
 
© Abhishek Gulati, 2009 
All Rights Reserved 
 
FACTORS INFLUENCING PLACENTAL TRANSFER OF LOPINAVIR:  
BINDING, UPTAKE AND EFFLUX 
A Thesis submitted in partial fulfillment of the requirements for the degree of 
Master of Science at Virginia Commonwealth University 
 
by 
 
ABHISHEK GULATI 
Bachelor of Pharmacy, Jamia Hamdard University, India, 2003 
Master of Pharmacy (Pharmaceutics), Punjabi University, India, 2005 
 
Director: PHILLIP M. GERK, Pharm.D., Ph.D. 
Assistant Professor, Department of Pharmaceutics 
 
 
 
 
 
 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
June 2009 
   
 
 
 
 
Dedicated to my Respected Parents,  
my brother Amit  
and  
my loving wife, Puja 
 
 
 
 
 
 
 
 
 
 ii
   
Acknowledgements 
 
A journey is easier when you travel together. Interdependence is certainly more 
valuable than independence. This thesis is the result of research work whereby I have 
been accompanied and supported by many people. It is a pleasant aspect that I have now 
the opportunity to express my gratitude for all of them. 
I would like to start this chain of my gratitude by mentioning the names of the 
most important persons in my life, my parents, Mr. Anil Gulati and Mrs. Kulbeer 
Gulati. Words prove a meager media to write down my feelings for them. Their love and 
support will remain indelible forever in my life. No words acknowledge the love and 
support I have received from my brother, Dr. Amit Gulati. I thank him for encouraging 
me all my life. I am extremely fortunate in having the best of family that God could 
provide on this earth. 
I would like to thank my mentor and advisor, Dr. Phillip M. Gerk for all his 
enthusiastic support during my time here at VCU. His scientific inputs and patient 
instructions always helped me. Thanks for all his genuine support whenever asked for. 
I owe my special thanks to Dr. Douglas Boudinot for all his help with the protein 
binding studies. His expertise in the field of pharmacokinetics helped me learn a lot and 
has boosted my interest in the field. His inputs and suggestions have been a very 
important part in completing this research work. 
 iii
   
I also owe special thanks to Drs. Scott W. Walsh, Douglas Sweet and Jürgen 
Venitz for their suggestions and words of advice. Dr. Walsh’s expertise on placental 
physiology, Dr. Sweet’s valuable suggestions with the BeWo cell culture model and Dr. 
Venitz’s inputs during the PK/PD/DT research group meetings and otherwise helped me 
accomplish this work. 
I acknowledge the financial support for this project from National Institute of 
Health Grant 1P60-MD002256 and the Higher Education Equipment Trust Fund of 
Virginia. I also thank VCU School of Pharmacy, Department of Pharmaceutics for the 
financial support for my graduate education. I would also like to mention the name of Dr. 
Kenneth Audus (The University of Kansas Medical Center, Kansas City, KS) for 
providing us with the BeWo cells and also to Pallabi Mitra for her help in growing the 
cells. 
I would like to acknowledge the support given to me by my friends and seniors 
who at all junctions made me cheerful and reduced my tensions from time to time. I 
would like to specially mention the names of Dave, Soniya, Satjit, Pravin, Lokesh, 
Kumar, Taghreed, Bhawana, Priya, Megha, Prajakta and Swati for their encouragement at 
different phases of this thesis. 
I would also like to thank a lot to God, with whose grace and beatitude, I moved 
through this venture.  
 iv
   
At the last and most important I thank a lot to my wife, Puja, for her support 
during the past years. She was a distant companion in all my ups and downs in the 
Graduate Program here at VCU. I acknowledge all the encouragement and love offered 
by her. 
 v
 Table of Contents 
Page 
Acknowledgements ............................................................................................................ iii 
List of Tables .................................................................................................................... ix 
List of Figures ..................................................................................................................... x 
List of Abbreviations .......................................................................................................xiii 
Chapter  
 1    Introduction....................................................................................................... 1 
1.1   Highly Active Antiretroviral Therapy during Pregnancy..................... 4 
1.2   Expression of ABC Transporters in the Placenta ................................. 6 
1.2.1   ABCB1 (P-glycoprotein)................................................................... 6 
1.2.2   ABCG2 (Breast Cancer Resistance Protein) ..................................... 8 
1.2.3   ABCC family (Multidrug Resistance Proteins)................................. 9 
1.3   HIV Protease Inhibitors and ABC Transporters................................. 11 
1.4   Expression of OATP Transporters in the Placenta............................. 19 
1.5   HIV Protease Inhibitors and OATP Transporters............................... 22 
1.6   Plasma Protein Binding Issues ........................................................... 24 
1.7   Intracellular Accumulation of HIV Protease Inhibitors ..................... 25 
1.8   Why Lopinavir/ Ritonavir?................................................................. 28 
1.9   Why BeWo Cell Line as a Model?..................................................... 30 
2 Significance, Hypothesis and Specific Aims .................................................. 32 
3 Materials and Methods.................................................................................... 35 
 vi 
   
3.1   Protein Binding Studies ...................................................................... 35 
3.2   BeWo Cell Culture Studies................................................................. 40 
 3.2.1   Cell culture medium .................................................................. 40 
 3.2.2   Culturing of BeWo cells ............................................................ 41 
 3.2.3   Growth of BeWo cells on standard cell culture plates .............. 41 
 3.2.4   Efflux experiments .................................................................... 42 
 3.2.4.1   Preliminary time course experiments ..................................... 42 
 3.2.4.2   Efflux experiments at 37°C and 4°C ...................................... 43 
 3.2.5   Obtaining cell pellets for cell pellet binding experiments......... 44 
 3.2.6   BeWo cell and placental tissue homogenate binding experiments 
with 3H-lopinavir .................................................................................. 44 
 3.2.7   Uptake experiments ................................................................... 45 
 3.2.7.1   Preliminary time course experiments ..................................... 45 
 3.2.7.2   Uptake experiments at 37°C and 4°C..................................... 46 
 3.2.8   Statistical Analysis .................................................................... 47 
4 Results and Discussion.................................................................................... 48 
4.1   Protein Binding Studies ...................................................................... 48 
4.2   BeWo Cell Culture Studies................................................................. 61 
 4.2.1   Experiments to differentiate between uptake and binding ........ 64 
 4.2.1.1   Efflux of 3H-lopinavir in BeWo cells ..................................... 64 
 4.2.1.2   Binding of 3H-lopinavir in BeWo cells .................................. 68 
 4.2.1.3   Uptake of 3H-lopinavir in BeWo cells.................................... 70 
 vii
   
 
5 Conclusions..................................................................................................... 74 
Literature cited .................................................................................................................. 76 
Appendices........................................................................................................................ 89 
I IRB Approval and Informed Consent Form.................................................... 89 
II BeWo cell culture protocol ............................................................................. 94 
III Lowry protein assay ........................................................................................ 99 
IV Results of the preliminary experiments performed with 3H-lopinavir using 
BeWo cell line............................................................................................... 100 
Vita.................................................................................................................................. 110 
 
 viii
   
List of Tables 
Page 
Table 1: Effect of physiological changes observed during pregnancy on pharmacokinetics, 
in general............................................................................................................................. 3 
Table 2: Summary of OATP transporters expressed in the placenta ................................ 20 
Table 3: Clinical data for patients undergoing C-section delivery following normal 
pregnancy .......................................................................................................................... 37 
Table 4: Summary of clinical data of the pregnant patients with their individual mean 
unbound fractions of 3H-lopinavir. ................................................................................... 50 
 ix
   
List of Figures 
Page 
Figure 1: Rapid Equilibrium Dialysis ............................................................................... 39 
Figure 2: Cord serum binding experiments to determine the time to equilibrium for 3H-
lopinavir ............................................................................................................................ 49 
Figure 3: Lopinavir binding to AAG: Lopinavir binding at varying drug concentrations 
(0.1-30 µM) to 7 µM AAG (filled circles) and at 0.1-100 µM to 23 µM AAG (open 
squares) ............................................................................................................................. 52 
Figure 4: Lopinavir binding to AAG: Bound lopinavir concentrations normalized for AAG 
concentration as a function of unbound lopinavir concentrations. AAG: 7 µM (filled 
circles); 23 µM (open squares).......................................................................................... 53 
Figure 5: Lopinavir binding to HSA: Lopinavir binding at varying drug concentrations 
(0.1-30 µM) to 15 µM HSA (filled circles), and at 0.1-100 µM lopinavir to 152 µM (open 
squares) and 758 µM HSA (filled triangles)..................................................................... 55 
Figure 6: Lopinavir binding to HSA: Bound lopinavir concentrations normalized for HSA 
concentration as a function of unbound lopinavir concentrations. HSA: 15 µM (filled 
circles); 152 µM (open squares); 758 µM (filled triangles).............................................. 56 
Figure 7: Effect of ritonavir on lopinavir binding to AAG: Lopinavir binding to 9 µM 
AAG at various concentrations of lopinavir (0.1-30 µM) in the presence of ritonavir (0, 1, 
10, 25, or 50 µM; z, {, , , ▲, respectively)............................................................. 59 
 x
   
Figure 8: Effect of ritonavir on lopinavir binding to HSA: Lopinavir binding to 530 µM 
HSA at various concentrations of lopinavir (0.1-30 µM) in the presence of ritonavir (0, 1, 
10, or 100 µM; z, {, , , respectively) ...................................................................... 60 
Figure 9: Efflux of 3H-lopinavir (0.32 µM) in the presence or absence of verapamil 
(100µM) at 37°C or 4°C ................................................................................................... 65 
Figure 10: Efflux of 3H-lopinavir (0.32 µM) in the presence or absence of GF120918 
(1µM) or ritonavir (10 µM)............................................................................................... 67 
Figure 11: Fraction unbound of 3H-lopinavir in the presence or absence of verapamil 
(100µM) or ritonavir (10 µM) at 37°C and 4°C ............................................................... 69 
Figure 12: Uptake of 3H-lopinavir (0.32 µM) in the presence or absence of verapamil 
(100µM) at 37°C or 4°C ................................................................................................... 71 
Figure 13: Uptake of 3H-lopinavir (0.32 µM) in the presence or absence of 
bromosulfophthalein (50 µM) or taurocholate (100 µM) ................................................. 73 
Figure 14: Appendix IV: Uptake of 3H-lopinavir (0.32 µM) in the presence or absence of 
verapamil (100µM) ........................................................................................................... 96 
Figure 15: Appendix IV: Uptake of 3H-lopinavir (0.32 µM) in the presence or absence of 
verapamil (100µM) ........................................................................................................... 97 
Figure 16: Appendix IV: Efflux of 3H-lopinavir (0.32 µM) in the presence or absence of 
verapamil (100µM) ........................................................................................................... 98 
Figure 17: Appendix IV: Efflux of 3H-lopinavir (0.32 µM) in the presence or absence of 
sodium orthovanadate (500µM)........................................................................................ 99 
 xi
   
Figure 18: Appendix IV: Efflux of 3H-lopinavir (0.32 µM) in the presence or absence of 
verapamil (100µM) ......................................................................................................... 100 
Figure 19: Appendix IV: Uptake experiment with 3H-lopinavir (0.32 µM) and verapamil 
(100 µM) at 37°C and 4°C.............................................................................................. 102 
Figure 20: Appendix IV: Uptake experiment with 3H-lopinavir (0.32 µM) and verapamil 
(100 µM) at 37°C and 4°C.............................................................................................. 103 
Figure 21: Appendix IV: Efflux experiment with 3H-lopinavir (0.32 µM) and verapamil 
(100 µM) at 37°C and 4°C.............................................................................................. 104 
 xii
   
List of Abbreviations 
 
AAG α1-acid glycoprotein 
ABC ATP-binding cassette 
ABCB1 ATP-binding cassette transporter isoform B1; P-glycoprotein (P-gp), Multidrug Resistance 1 
(MDR1) 
ABCB4 ATP-binding cassette transporter isoform B4; Multidrug Resistance 3 (MDR3) 
ABCC1 ATP-binding cassette transporter isoform C1; Multidrug resistance protein 1 (MRP1) 
ABCC11 ATP-binding cassette transporter isoform C11; Multidrug resistance protein 8 (MRP8) 
ABCC2 ATP-binding cassette transporter isoform C2; Multidrug resistance protein 2 (MRP2) 
ABCC3 ATP-binding cassette transporter isoform C3; Multidrug resistance protein 3 (MRP3) 
ABCC4 ATP-binding cassette transporter isoform C4; Multidrug resistance protein 4 (MRP4) 
ABCC5 ATP-binding cassette transporter isoform C5; Multidrug resistance protein 5 (MRP5) 
ABCC7 ATP-binding cassette transporter isoform C7; Multidrug resistance protein 7 (MRP7) 
ABCG2 ATP-binding cassette transporter isoform G2; Breast cancer resistance protein (BCRP) 
AIDS Acquired immunodeficiency syndrome 
ANOVA Analysis of variance 
ATP Adenosine triphosphate 
BCRP Breast cancer resistance protein (human isoform) 
Bcrp1 Breast cancer resistance protein 1 (rodent ortholog) 
BMI Body mass index 
BSA Bovine serum albumin 
 xiii
   
BSP Bromosulfophthalein 
CYP Cytochrome P450 
CYP3A4 Cytochrome P450 isoform 3A4 
DMEM Dulbecco’s modified Eagle’s medium 
DNP-SG 2, 4-dinitrophenyl-S-glutathione 
DPBS Dulbecco’s Phosphate Buffered Saline 
EDTA Ethylene diamine tetra-acetic acid 
EMS Ethyl methanesulfonate 
FBS Fetal bovine serum 
FDA Food and Drug Administration 
GSH Reduced glutathione 
HAART Highly Active Anti-Retroviral Therapy 
hCC Human choriocarcinoma cell lines 
HEK Human embryonic kidney 
HIV Human immunodeficiency virus 
hL Human liver 
hPl Human placenta 
HSA Human serum albumin 
hTCs Human trophoblast cells 
hTr Human trophoblast cells 
MDCK Madin-Darby canine kidney 
 xiv
   
MDR1 Multidrug resistance 1 (human isoform) 
MDR3 Multidrug resistance 3 (human isoform) 
MRP Multidrug resistance protein (human isoform) 
MRP8 Multidrug resistance associated protein 8 (human isoform) 
OATP Organic anion transporting polypeptides 
OATP1A2 Organic anion transporting polypeptide (human) isoform 1A2 
OATP1B1 Organic anion transporting polypeptide (human) isoform 1B1 
OATP1B3 Organic anion transporting polypeptide (human) isoform 1B3 
OATP2B1 Organic anion transporting polypeptide (human) isoform 2B1 
OATP3A1 Organic anion transporting polypeptide (human) isoform 3A1 
OATP4A1 Organic anion transporting polypeptide (human) isoform 4A1 
PBMC Peripheral blood mononuclear cell 
PBS phosphate buffered saline 
P-gp P-glycoprotein 
PI Protease inhibitor 
RED Rapid equilibrium dialysis 
Rho123 Rhodamine 123 
RT-PCR Reverse transcription polymerase chain reaction 
SLCO Solute carrier organic anion transporter superfamily 
TC Taurocholate  
 
 xv
   
 
 
 
Abstract 
 
 
 
FACTORS INFLUENCING PLACENTAL TRANSFER OF LOPINAVIR:  
BINDING, UPTAKE AND EFFLUX 
By Abhishek Gulati, B. Pharm., M. Pharm. 
A Thesis submitted in partial fulfillment of the requirements for the degree of  
Master of Science at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2009 
 
Major Director:  Phillip M. Gerk, Pharm.D., Ph.D. 
Assistant Professor, Department of Pharmaceutics 
 
 
 
 
HIV protease inhibitors are an important component of Highly Active 
Antiretroviral Therapy used to treat HIV infected pregnant women. They have a low 
placental transfer and are highly plasma protein bound. The purpose of this thesis was to 
characterize the factors limiting placental passage and fetal exposure to lopinavir. These 
factors include lopinavir plasma protein binding and uptake, cellular binding, and efflux of 
lopinavir in the placental trophoblast cells.  
First, we determined the unbound fraction of lopinavir in cord blood and 
characterized the binding of lopinavir to α1-acid glycoprotein (AAG) and human serum 
 xvi
   
albumin (HSA), and displacement by ritonavir. Serum was obtained from cord blood from 
placentae obtained after cesarean section of healthy non-HIV infected women (n=4). The 
unbound fraction of lopinavir in serum obtained from this cord blood was 0.02 ± 0.01. The 
unbound fraction of lopinavir in separately obtained maternal serum samples (n=4) was 
0.009 ± 0.001, which was not significantly different from that observed with cord serum 
samples. Varying concentrations of lopinavir, AAG, and HSA in buffer solutions were 
then used to characterize the lopinavir binding. The data were fit to obtain the number of 
binding sites (N) and equilibrium dissociation constant (KD). Binding of lopinavir to AAG 
(7-23 µM) was saturable with KD of 5.0 ± 1.1 µM and N of 1.2 ± 0.2. At low HSA 
concentrations (15-152 µM), lopinavir binding KD was 24.3 ± 8.7 µM and N was 1.1 ± 0.4; 
however at 758 µM, lopinavir binding was essentially unsaturable. Additionally, lopinavir 
binding to AAG and HSA was not sensitive to ritonavir within the range of therapeutic 
concentrations. 
Next, we examined lopinavir uptake, binding and efflux using the BeWo human 
trophoblast cell culture model. BeWo cells were treated with 3H-lopinavir in the absence or 
presence of inhibitors of ATP- Binding Cassette transporters. The radioactivity was then 
measured in the buffer and the cells after incubating for different time intervals and at two 
temperatures. Verapamil (100µM) stimulated apparent efflux of 3H-lopinavir by two fold, 
possibly due to ABCC2. In addition, this efflux process was 75% inhibited by reduced 
temperature (4°C). Ritonavir (10 µM) also stimulated 3H-lopinavir efflux, whereas 
GF120918 (1 µM) had no effect. Reduced temperature (4°C), verapamil (100 µM) or 
ritonavir (10 µM) individually did not significantly affect the binding of 3H-lopinavir to 
 xvii
   
cell homogenates. However, slight but significant binding displacement by verapamil at 
4°C was observed. 3H-lopinavir uptake was not sensitive to verapamil, 
bromosulfophthalein, taurocholate or to reduced temperature suggesting uptake involves 
diffusion rather than Organic Anion Transporting Polypeptide transporters. The results 
suggested that interplay between cellular binding and ABC efflux transporters, in addition 
to simple diffusion, determines the extent of 3H-lopinavir distribution into BeWo cells. 
 xviii
  
 
 
 
CHAPTER 1 INTRODUCTION 
 
 
The placenta is a complex organ that forms an interface between the maternal and 
the fetal circulation during the gestation period. It functions in the exchange of nutrients, 
respiratory gases, and metabolic waste, and is also a source of hormones. Additionally, it 
may limit fetal exposure to various xenobiotics in the maternal circulation. Drug 
concentrations achieved in the fetus depend on the maternal drug concentration, kinetics of 
drug transfer across the placenta, and placental and fetal drug metabolism. The rate and 
extent of drug transfer depends on physicochemical properties of the drugs and the 
physiological characteristics of the maternal-placental-fetal unit (Syme et al., 2004). The 
properties of drugs that may affect the extent of placental transfer include their molecular 
weight, pKa, lipid solubility, and plasma protein binding. Also, several types of uptake and 
efflux transporters are present on the maternal facing (brush-border or apical) as well as the 
fetal facing (basolateral) side of syncytiotrophoblast, which potentially modulate the 
placental passage of drugs intended to treat the mother, the fetus or both. Therefore, these 
transporters may limit the passage of some drugs intended for maternal or fetal treatment 
and thus, alter drug exposure. Among them are the ATP Binding Cassette (ABC) and the 
Organic Anion Transporting Polypeptide (OATP) transporters. ABC transporters are efflux 
transporters that utilize the energy of ATP hydrolysis to transfer substances out of the cells, 
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usually toward maternal circulation. OATPs are plasma membrane transport proteins that 
mediate the active cellular uptake of a variety of compounds. 
Pregnancy results in physiologic changes that not only concern the mother but also 
the fetus and the placenta. Besides changes observed throughout the pregnancy in the 
cardiovascular system, respiratory system, GI system, kidneys, and the uterus, there are a 
number of significant changes that occur in the placenta during gestation. Some of these 
physiological changes are summarized below in Table 1 (Loebstein et al., 1997; Anderson, 
2005). These physiological changes, which may affect all four pharmacokinetic processes, 
may result in altered drug concentrations during pregnancy. These changes may also affect 
the expression of various transporters present in the placenta and as a result, may affect the 
extent of placental drug transfer. 
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Table 1: Effect of physiological changes observed during pregnancy on pharmacokinetics, 
in general (Loebstein et al., 1997; Anderson, 2005). 
ABSORPTION 
• Reduction in gastric acid secretion causes an increase in gastric pH 
• Decrease in intestinal motility causes an increase in gastric emptying time and intestinal transit 
time 
• Nausea and vomiting, which are pronounced during the earlier stages of pregnancy, may also 
affect drug absorption 
DISTRIBUTION 
• Total body water, plasma volume and body fat stores also increase and may affect drug 
distribution 
• Plasma protein concentrations also change during pregnancy. Albumin concentrations decrease 
whereas concentrations of α-acid glycoprotein are equivocal. 
• Volume of distribution increases which causes a decrease in peak drug concentrations 
METABOLISM 
• Estrogen and progesterone levels increase, which may affect the activity and expression of 
many metabolizing enzymes. Activity of CYP3A4, 2D6, 2C9 and 2A6 increases whereas that of 
CYP1A2 and 2C19 decreases during pregnancy 
EXCRETION 
• Renal plasma flow and glomerular filtration rate increase, which increases the renal clearance of 
a drug 
• Activity and expression of different transporters are also altered 
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HIGHLY ACTIVE ANTIRETROVIRAL THERAPY DURING PREGNANCY 
Human Immunodeficiency Virus (HIV) - infected patients are defined as having the 
Acquired Immunodeficiency Syndrome (AIDS) if they have CD4 cell count of less than 
200/mm3. Since the onset of the epidemic, close to 60 million people have been infected 
with the virus, with almost 20 million dying from its complications. Of the more than 40 
million people with HIV infection today, close to half of them are women, and more than 3 
million are children under the age of 15 (Libman and Makadon, 2007). To treat HIV 
infected patients, multiple antiretroviral drugs are used in what is known as Highly Active 
Antiretroviral Therapy (HAART). Over the past decade, HAART has led to a significant 
increase in life expectancy, at least in drug-naïve patients. Recent studies with newly 
discovered agents have resulted in an extension of this benefit to treatment-experienced 
patients as well, with over 60% of the subjects in a study achieving maximal virologic 
suppression when treated with raltegravir, the first drug of a new class of HIV drugs, the 
integrase inhibitors. According to the authors, its combination with darunavir and 
etravirine may extend the benefit to over 90% of the patients. Similar results may also be 
expected with maraviroc, a newly developed chemokine receptor antagonist (Conway, 
2009).  
In pregnant HIV infected patients, however, HAART serves two goals, providing 
adequate treatment for the mother and preventing viral transmission to the fetus. The use of 
HAART regimens has led to a significant reduction in occurrence of perinatal transmission 
to less than 2% (Watts, 2006). The use of different drug combinations with the inclusion of 
novel compounds may, however, result in unacceptable side effects in clinical practice that 
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may not have been detectable during clinical trials. These have not only increased the 
chances of short-term toxicities but also long-term impact on the mother and the child. 
Because of toxicities observed after use of these antiretroviral drugs in pregnant women, 
there have been guidelines published for use of these drugs in pregnant HIV-infected 
women (http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf). Based on the clinical data 
available, NIH has divided the antiretroviral drugs into four categories for their use in 
pregnant patients: recommended agents, alternate agents, drugs for use in special 
circumstances, and drugs for which there is insufficient data to recommend use. According 
to 2009 guidelines, lopinavir/ ritonavir is the only recommended agent in the category of 
protease inhibitors for use in HIV-infected pregnant patients 
(http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf). 
As mentioned earlier, different physiological changes that occur during pregnancy 
may also alter the pharmacokinetics of different drugs. In pregnancy, the concentrations of 
nucleoside and non-nucleoside reverse transcriptase inhibitors may not change 
significantly but concentrations of protease inhibitors (PI) are significantly reduced 
(Marzolini and Kim, 2005). As protease inhibitors are an integral part of HAART, lower 
concentrations may result in treatment failure and poor therapeutic outcomes. Thus, the 
observed physiological changes during pregnancy may necessitate dose adjustments to 
achieve therapeutic concentrations in pregnant women.  
There are various ABC transporters that are expressed in the placenta, of which 
HIV protease inhibitors are known to be substrates of many of them. Most of the HIV 
protease inhibitors are administered with ritonavir, which acts to inhibit excretion mediated 
 5
   
by ABCB1 and metabolism mediated by CYP3A4, thus causing an increase in 
concentrations of the HIV protease inhibitors (Huisman et al., 2001). The drug-transporter 
interactions together with a change in expression of these transporters that may occur 
during pregnancy, there may be an affect on the therapeutic outcome. Thus, there is a need 
to know which transporters and to what extent they are expressed in the placenta. 
 
EXPRESSION OF ABC TRANSPORTERS IN THE PLACENTA 
ABCB1 (P-glycoprotein): 
The expression, localization and function of P-glycoprotein (P-gp) in the placenta 
have been reviewed (Ceckova-Novotna et al., 2006). P-gp, encoded by the multi drug 
resistance 1 (MDR1/ ABCB1) gene, is present on the apical (brush-border) 
syncytiotrophoblast membrane and actively extrudes many substrates, including a wide 
range of drugs. The efflux of lipophilic or slightly charged compounds from the cell takes 
place with the utilization of energy from ATP hydrolysis. Rhodamine 123 (Rho123), a well 
known ABCB1 substrate, has a higher maternal-to-fetal transplacental passage in the 
presence of the ABCB1 inhibitors PSC833, cyclosporine A, quinidine, and 
chlorpromazine. The fetal-to-maternal passage of Rho123 decreases in the presence of 
PSC833, cyclosporine A, and quinidine (Pavek et al., 2003). These data indicate that the 
transplacental passage of Rho123 is in part directed by ABCB1. Atkinson et al. carried out 
RT-PCR and western blotting studies in placenta, primary cytotrophoblast cell cultures and 
BeWo, JAr, and JEG choriocarcinoma cell lines (Atkinson et al., 2003). They found 
ABCB1 to be absent or expressed minimally in BeWo and JEG cell lines (antibodies used 
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were clone F4 or C219). In the syncytiotrophoblast, ABCB1 was present predominantly on 
the apical side (maternal-facing). Western blotting analysis carried out by Nagashige et al., 
with human placental membrane vesicles indicated the localization of ABCB1 on the 
apical membrane (Nagashige et al., 2003). The primary antibody used by the authors 
against ABCB1 was C219. In other studies, no ABCB1 expression was revealed at the 
mRNA and protein levels (antibody used – C219 anti-ABCB1 monoclonal antibody) in 
BeWo cells (Magnarin et al., 2008). The low level or absence of ABCB1 expression in 
BeWo cells observed by these authors was contrary to the higher level observed by others 
(Ushigome et al., 2000; Utoguchi et al., 2000). The antibodies used by these authors were 
mouse monoclonal antibody C219 or P170-glycoprotein, multidrug-resistance-related 
clone JSB-1 (Ushigome et al., 2000) and antihuman C219 monoclonal antibody (Utoguchi 
et al., 2000); however C219 antibody also recognizes MDR3 (ABCB4) which may have 
resulted in a false positive result for ABCB1 expression. Ceckova-Novotna et al. mention 
that expression of ABCB1 seemed to differ among particular clones of BeWo cells, as they 
also observed an undetectable expression of ABCB1 mRNA when they used BeWo cells 
from the same source as Atkinson et al. (Ceckova-Novotna et al., 2006). In contrast to 
ABCB1, MDR3/ABCB4 gene product transports a limited number of substrates. The 
expression of ABCB4 in human placenta has been reported (Patel et al., 2003); however, 
its functional significance in the placenta is unknown. It is present in the syncytial 
basolateral membrane and cells lining the fetal capillaries (Evseenko et al., 2006b), and is 
upregulated four fold in third trimester placentae compared to first trimester (Patel et al., 
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2003), in contrast to ABCB1, which is expressed more abundantly during the early 
gestation (Sun et al., 2006). 
 
ABCG2 (Breast Cancer Resistance Protein): 
Breast Cancer Resistance Protein (BCRP, ABCG2) confers resistance to 
hydrophobic/ anionic xenobiotics like mitoxantrone, topotecan derivatives, and 
anthracyclines. It is present on the apical side of the syncytiotrophoblast and its substrates 
include a wide variety of anticancer agents, organic cations and lipophilic conjugates 
(Evseenko et al., 2006a). ABCG2 is known as a "half-transporter" as it is reported to be 
composed of just one transmembrane region and one ATP-binding domain compared to 
other ABC transporters which are composed of two transmembrane regions and two ATP-
binding domains (Brangi et al., 1999), although the active form is thought to be a dimer. 
Mao et al. have reviewed the role of ABCG2 in multi-drug resistance and drug disposition 
(Mao and Unadkat, 2005). Expression of ABCG2 in BeWo cells (antibody used – 
monoclonal anti-ABCG2 antibody – clone BXP-21) has been reported (Magnarin et al., 
2008). Functional evidence of Bcrp1 activity in the mouse placenta was established by 
Jonker et al. (Jonker et al., 2000). They showed that treatment with a ABCG2 inhibitor 
GF120918, which also inhibits ABCB1, decreases plasma clearance and hepatobiliary 
excretion of topotecan and increases absorption of this anticancer drug from the small 
intestine in ABCB1 knockout mice. In pregnant GF120918 treated ABCB1 deficient mice, 
the relative fetal concentration of topotecan was found to be 2-fold higher than that in 
pregnant vehicle treated mice (Jonker et al., 2000). The authors explained that topotecan 
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was a weaker substrate for ABCB1 and suggested the increase in bioavailability was due to 
inhibition of ABCG2 by GF120918, resulting in increased intestinal absorption and 
decreased biliary excretion of the agent. Also, inhibition of ABCG2 in the placenta may 
have resulted in higher fetal topotecan concentrations. 
 
ABCC family (Multidrug Resistance Proteins): 
Evseenko et al. have reviewed different ABC transporters involved in the active 
transport across the human placenta (Evseenko et al., 2006a). The multidrug resistance 
protein (MRP) family of drug transporters has nine members. They are organic anion 
transporters; however, ABCC1, ABCC2, and ABCC3 also transport certain neutral drugs. 
Their substrate range is much narrower compared to ABCB1, and are involved in the 
efflux of toxic fetal metabolites, in particular unconjugated bilirubin and bile acids. They 
are also involved in the removal of glutathiolated, glucuronidated, or sulfated metabolites 
from cells. St-Pierre et al. examined if members of the ABCC family were expressed in 
term placenta (St-Pierre et al., 2000). Immunofluorescence and immunoblotting studies 
carried out by the authors showed that ABCC2 was localized to the apical 
syncytiotrophoblast membrane, where as ABCC1 and ABCC3 were predominantly 
expressed in blood vessel endothelia with some evidence for expression in the apical 
syncytiotrophoblast (St-Pierre et al., 2000). However, ABCC1 is also reported to be 
localized on the basolateral side of the placental membrane. Atkinson et al. carried out RT-
PCR and western blotting studies in placenta, primary cytotrophoblast cell cultures and 
BeWo, JAr, and JEG choriocarcinoma cell lines, and found ABCC1 to be expressed 
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ubiquitously (Atkinson et al., 2003). In the syncytiotrophoblast, ABCC1 was present on 
the basolateral side. Western blotting analysis carried out by Nagashige et al., with human 
placental membrane vesicles indicated the localization of ABCC1 on the basolateral 
membrane (Nagashige et al., 2003). Functional evidence for apical localization of ABCC1 
has been observed by our laboratory (Vaidya et al., 2009). These studies indicated the 
involvement of an apical ABC transporter that was inhibited by MK571, dipyridamole, and 
verapamil in the efflux of 2, 4-dinitrophenyl-S-glutathione (DNP-SG) from the villous 
tissue. Their results were consistent with their 3H-DNP-SG transport data with Sf9 
membrane vesicle experiments. The authors supported this by explaining that in cultured 
placental villous tissue model, the fetal capillaries are collapsed and basolateral DNP-SG 
efflux would not be expected. Histological examination of the villous tissue revealed that 
fetal capillary endothelial vessels were not exposed to the medium, thus supporting the 
argument of apical localization of ABCC1 (Vaidya et al., 2009). In BeWo cells, expression 
of ABCC1 (antibody used – A23 anti-ABCC1 polyclonal antibody) has been reported in 
other studies, however, the authors did not discuss the localization of the transporter 
(Magnarin et al., 2008). Pascolo et al. compared the expression of ABCC1, ABCC2, 
ABCC3, and ABCC5 in human placental tissue and in BeWo cells by real-time RT-PCR 
analysis (Pascolo et al., 2003). They expressed the protein expression by Western blot. The 
authors found ABCC1 and ABCC3 to be most abundantly expressed in the placenta. Only 
ABCC1 was highly expressed in BeWo cells compared to ABCC2, ABCC3, and ABCC5 
that were weakly expressed (Pascolo et al., 2003). Langmann et al. carried out real-time 
reverse transcription-PCR expression profiling of the complete human ABC transporter 
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superfamily in various tissues and have documented the ABCC4, -5, and -7 mRNA 
expression in the placenta in addition to the above mentioned ABCC transporters 
(Langmann et al., 2003). Schuetz et al. have investigated if overexpression and 
amplification of the ABCC4 gene was correlated with ATP-dependent efflux of some 
dideoxynucleosides, which are a common component of HAART (Schuetz et al., 1999). 
The two were found to be correlated and overexpression of ABCC4 mRNA and protein 
severely impaired the antiviral efficacy of the studied reverse transcriptase inhibitor drugs. 
Higher resistance to the studied nucleoside monophosphate analogs and amplification of 
the ABCC4 gene was correlated with enhanced drug efflux (Schuetz et al., 1999). ABCC5 
mRNA as well as protein expression in the human placenta has been reported and its 
functional activity has been measured in the placental basal membrane vesicles and fetal 
endothelium (Meyer Zu Schwabedissen et al., 2005). However, localization and 
physiological role of ABCC7 in pregnancy still remains obscure (Evseenko et al., 2006a). 
Expression of ABCC11 (MRP8) is also reported in the placenta (Tammur et al., 2001; 
Yabuuchi et al., 2001). Its substrate specificity appears as broad as that of ABCC1 and 
ABCC2. Although the ABCC family plays important roles in other barrier epithelia, their 
impact and role in the human placenta is not as clearly established. 
 
HIV PROTEASE INHIBITORS AND ABC TRANSPORTERS 
 HIV protease inhibitors, as substrates of ABC transporters, have been the targets of 
many studies that have been carried out to see the effect of pharmacokinetic changes 
during pregnancy, on the placental transfer of this category of drugs. The literature shows 
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several cases in which efflux transporters are responsible for low drug concentrations 
reaching the fetus. For example, a deficiency in mouse placental ABCB1 has been shown 
to enhance fetal susceptibility to chemically induced birth defects by avermectins (Lankas 
et al., 1998). Similarly, Smit et al. showed that 2.4-, 7-, or 16-fold more [3H]-digoxin, 
[14C]-saquinavir, or paclitaxel, respectively, entered the ABCB1 deficient Abcb1a-/-/1b-/- 
fetuses than entered wild type fetuses in the study carried out in mice (Smit et al., 1999). 
They also used the ABCB1 inhibitors PSC833 or GG918 to show that blocking ABCB1 
using these inhibitors resulted in increased transplacental passage of these drugs into the 
fetus. Molsa et al. observed similar results in studies carried out with human placentae, in 
which preperfusion with PSC833 increased the maternal-to-fetal transfer of saquinavir by 
7.9-fold (0.18% ± 0.09% vs 1.4% ± 0.67%), and preperfusion with GG918 increased it by 
6.2-fold (0.18% ± 0.09% vs 1.1% ± 0.39%) (Molsa et al., 2005). The authors also observed 
108-fold higher saquinavir transfer in the fetal-to-maternal direction than from maternal to 
fetal direction (0.18% ± 0.09% vs 19.5% ± 14.5%). PSC833 did not affect saquinavir 
transfer in the fetal-to-maternal direction (16.6% ± 14.2% vs 19.5% ± 14.5%), possibly 
because it was already relatively high. The authors also found that ABCB1 expression was 
correlated with PSC833-induced change in saquinavir transfer, but did not observe an 
effect of ABCB1 polymorphism on the PSC833- or GG918-induced change in saquinavir 
transfer in a small number of samples (Molsa et al., 2005). 
The interaction of HIV protease inhibitors with ABCB1 has been reported (Srinivas 
et al., 1998). At a concentration of 5 µM, ritonavir, nelfinavir, and indinavir significantly 
increased calcein fluorescence in CEM/ VBL100 cells in the calcein-AM assay, indicating 
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ABCB1 was inhibited. However, at a higher concentration of 50 µM, saquinavir was also 
observed to have an effect. This observed increase in calcein fluorescence was probably 
due to a decreased ABCB1 activity caused by the HIV protease inhibitors used in the 
study. The drugs caused a decrease in calcein-AM efflux, which was seen as an increased 
fluorescence. Thus, all four protease inhibitors studied were found to interact with ABCB1 
with affinities in the order ritonavir > nelfinavir > indinavir > saquinavir (Srinivas et al., 
1998). In the same study, all four drugs were also found to increase the calcein 
fluorescence in ABCC1+ CEM/VM-1-5 cells suggesting inhibition of ABCC1 by HIV 
protease inhibitors (Srinivas et al., 1998). 
In several different studies, ritonavir, saquinavir, indinavir and nelfinavir were 
observed to inhibit ABCB1 (Srinivas et al., 1998; Gutmann et al., 1999; Profit et al., 1999; 
Choo et al., 2000; Miller et al., 2000; Washington et al., 2000; Huisman et al., 2001). 
Ritonavir was the most potent of them. In a study by Drewe et al., ritonavir (IC50 = 0.2 
µM) was found to be a more potent ABCB1 inhibitor than the ABCB-reversing agent SDZ 
PSC833 (IC50 = 1.13 µM). The authors used porcine primary brain capillary endothelial 
cell monolayers as an in vitro system to study the effect of ABCB1 inhibition on the 
uptake of saquinavir into the cells. A 5.65-fold higher concentration of SDZ PSC833 was 
required to inhibit the ABCB1 mediated extrusion of saquinavir. The authors concluded 
that administering ritonavir with saquinavir may facilitate the brain uptake of the drug 
(Drewe et al., 1999). 
Sudhakaran et al. investigated the effect of PSC833, a known ABCB1 inhibitor, 
and ritonavir, on the clearance index of indinavir (Sudhakaran et al., 2008). They carried 
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out the dual in-vitro perfusion of the isolated human placenta and found an increase in 
clearance index of indinavir between control (0.25 ± 0.03) and PSC833 treatment (0.37 ± 
0.14). In contrast, clearance index of indinavir was observed to be unchanged between 
control (0.34 ± 0.14) and ritonavir treatment (0.39 ± 0.13) (Sudhakaran et al., 2008). The 
authors suggested the use of ABCB1 inhibitors to achieve higher transfer across the 
placenta for drugs which are substrates of ABCB1. However, since indinavir also interacts 
with ABCC1 (Srinivas et al., 1998) and ABCC2 (Huisman et al., 2002), it is possible that 
the above results may have been due to the contribution of other transporters. 
Some protease inhibitors have also been reported to be inducers of ABCB1 
expression. Vishnuvardhan et al. reported that acute treatment with lopinavir inhibits 
ABCB1 activity; however, on extended exposure lopinavir not only increased the efflux of 
rhodamine 123 but also the expression of ABCB1 protein and mRNA (Vishnuvardhan et 
al., 2003). The authors demonstrated that lopinavir potently inhibited ABCB1 mediated 
rhodamine 123 efflux in Caco-2 monolayer cells (IC50 = 1.7 µM). Upon chronic lopinavir 
exposure (72 hours) in LS180V cells, the content of intracellular rhodamine 123 was 
reduced by approximately 50%, which indicated increased efflux activity. In these cells, 
lopinavir induced ABCB1 mRNA and protein levels up to three-fold in a concentration 
dependent manner (Vishnuvardhan et al., 2003). 
The influence of important anti-HIV drugs on ABCG2 activity in vitro has also 
been determined (Weiss et al., 2007). The authors assessed the ABCG2 inhibition by an 
increase in pheophorbide A accumulation in MDCKII-ABCG2 cells and compared it with 
the corresponding parental cell line MDCKII lacking human ABCG2. The authors 
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observed the following IC50 values regarding ABCG2 inhibition by the following anti-HIV 
drugs: lopinavir (7.66 µM) < nelfinavir (13.5 µM) < delavirdine (18.7 µM) ≤ efavirenz 
(20.6 µM) < saquinavir (27.4 µM) < atazanavir (69.1 µM) < amprenavir (181 µM) < 
abacavir (385 µM). Nevirapine and zidovudine were found to have a weak inhibitory 
effect. They could not estimate the inhibitory effects of ritonavir and tipranavir because of 
their low solubility. Other drugs in the study like indinavir, didanosine, emtricitabine, 
lamivudine, stavudine, tenofovir, and zalcitabine, were found not to have an inhibitory 
ABCG2 effect (Weiss et al., 2007).  
Steady-state plasma concentrations in HIV-positive patients after administering the 
above drugs at their therapeutically used concentrations are reported in different studies. 
Mean steady-state peak (Cmax,ss) and trough concentrations (Cmin,ss) vary from 7.0±1.4 µM 
and 3.9±2.3 µM, respectively, for nelfinavir (dose = 1250 mg twice a day) to 35±20 µM 
and 15±10 µM, respectively, for delavirdine (dose = 400 mg thrice a day). Cmax,ss and 
Cmin,ss for lopinavir is reported as 15.6±5.9 µM and 11.3±4.6 µM (dose for lopinavir/ 
ritonavir as 400/100 mg twice daily); for ritonavir as 15.5±5.0 µM and 5.1±3.6 µM (dose 
administered as 600 mg every 12 hours); for atazanavir as 7.4±4.3 µM and 1.2±1.1 µM 
(dose for atazanavir/ ritonavir as 300/100 mg once daily); and for efavirenz (dose = 600 
mg once daily) as 12.9 ± 3.7 µM and 5.6 ± 3.2 µM (www.efactsonline.com).  
Gupta et al. investigated the effect of HIV protease inhibitors on ABCG2 efflux 
activity by measuring intracellular mitoxantrone fluorescence in human embryonic kidney 
(HEK) cells stably expressing wild-type ABCG2 (482R) and its two mutants (482T and 
482G) (Gupta et al., 2004). Ritonavir, saquinavir, and nelfinavir were found to inhibit 
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wild-type ABCG2 (482R) with IC50 values of 19.5 ± 0.8 µM, 19.5 ± 7.6 µM, and 12.5 ± 
4.1 µM, respectively. All the three drugs were observed to inhibit 482T and 482G with 
IC50 that was found to be twice that observed with 482R. Indinavir and amprenavir were 
found not to inhibit ABCG2 activity. In the same study, direct efflux of above mentioned 
radiolabelled drugs in HEK cells was studied. None of them were found to be substrates of 
ABCG2 (Gupta et al., 2004). 
ABCC inhibition by indinavir, amprenavir, ritonavir, lamivudine or zidovudine has 
been investigated (Olson et al., 2002). Of the drugs studied, only ritonavir was found to 
inhibit the functional activity of ABCC1. The inhibitory effects were studied in UMCC-
1/VP cells which over-express ABCC1 and the inhibitory activity was demonstrated by re-
sensitization of ABCC1 over-expressing cells to cytotoxic effects of etoposide, a cytotoxic 
compound (Olson et al., 2002). 
HIV protease inhibitors transfer poorly across the placenta. Cord/ maternal blood 
concentration ratios of protease inhibitors have been observed to range from 0.01 in case of 
indinavir to 0.27 in case of amprenavir (Marzolini et al., 2002; Chappuy et al., 2004b). In 
contrast, nucleoside and non-nucleoside reverse transcriptase inhibitors, which are much 
lesser plasma protein bound compared to protease inhibitors, transfer to a much greater 
extent. Cord/ maternal ratios range from 0.38 for didanosine to 1.32 for stavudine (Watts et 
al., 1991; Moodley et al., 1998; Mandelbrot et al., 2001; Marzolini et al., 2002; Chappuy et 
al., 2004a; Chappuy et al., 2004b). Similar results were observed in another study 
(Mirochnick et al., 2002). The authors in the above studies mention the lower placental 
transfer of protease inhibitors to be due to their efflux by ABCB1. However, the drugs are 
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known to be substrates of other ABC transporters as well. Therefore, other transporters in 
addition to ABCB1 may also contribute to the lower placental transfer observed with 
protease inhibitors. Also, the drugs’ high plasma protein binding may also contribute, as 
discussed later in this review. 
van Heeswijk et al. studied the pharmacokinetics of nelfinavir and its active 
metabolite hydroxy-t-butylamidenelfinavir (M8) during pregnancy and post partum in a 
group of patients (van Heeswijk et al., 2004). A 24% reduction in AUC0-12 of nelfinavir 
was observed during third trimester of pregnancy compared with post partum, though this 
reduction was not found to be statistically significant. The trough concentration (C12) was 
also reduced by 57% during pregnancy. In addition, AUC of M8 was reduced by 70% in 
pregnant women. The authors found just 3 out of 11 patients with therapeutic nelfinavir 
trough concentrations during third trimester of pregnancy compared to 6 patients post 
partum. The authors recommended the adjustment of nelfinavir doses during late 
pregnancy to maintain therapeutic plasma concentrations. A decrease in exposure with 
other protease inhibitors in pregnant women has also been observed. For saquinavir 
(Acosta et al., 2001) and indinavir (Unadkat et al., 2007), values for AUC0-8 h were 77% 
and 68% lower (respectively), antepartum compared to postpartum. Thus, dosage 
adjustments in pregnancy may be necessary for other protease inhibitors as well. 
Mathias et al. evaluated whether systemic clearance, bioavailability, or plasma 
protein binding of nelfinavir was altered during pregnancy in mice (Mathias et al., 2006). 
The mice replicated the pregnancy related changes observed in the oral nelfinavir 
disposition in pregnant women. The authors observed a significant decrease in nelfinavir 
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Cmax and AUC in pregnancy and a significant increase in oral plasma clearance of the drug, 
irrespective of whether or not it was normalized to body weight. The authors also 
determined if enhanced activity and/or expression of mouse CYP3A or ABCB1 or both 
were responsible for the reduced nelfinavir exposure observed during pregnancy. In 
contrast to oral administration, AUC and CL after intravenous administration were not 
significantly different in pregnant mice compared to those observed in non-pregnant mice. 
Bioavailability was significantly reduced in pregnant mice due to increased expression and 
activity of hepatic CYP3A. On the other hand, intestinal CYP3A as well as hepatic and 
intestinal ABCB1 expression were not found to be significantly different among pregnant 
and non-pregnant mice. Also, the percentage of nelfinavir unbound in plasma was found to 
be lower in pregnant mice compared to that in non-pregnant mice. This means that the 
increase in systemic clearance observed in pregnant mice was not due to a decrease in 
plasma protein binding. The authors concluded that the effect of pregnancy on nelfinavir 
disposition was due to a change in bioavailability and not due to change in plasma protein 
binding or systemic clearance of the drug. 
Thus, it can be seen that HIV protease inhibitors interact with ABC transporters 
present in the placenta. This is important information to know at the time the physician 
tailors the patient’s antiretroviral drug regimen. Besides ABC transporters, there are other 
transporters as well that are expressed in the placenta. ABC transporters being the major 
efflux transporters, there are other important uptake transporters like OATPs present in the 
placenta which may affect antiretroviral therapy outcomes. 
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EXPRESSION OF OATP -TRANSPORTERS IN THE PLACENTA 
OATPs are plasma membrane transport proteins that modulate the uptake of a 
variety of compounds. Substrates of OATPs include bile salts, steroid conjugates, thyroid 
hormones, and several therapeutic drugs and other xenobiotics. They are expressed on the 
apical as well as basolateral membranes of polarized cells in liver, kidneys, intestine and 
blood brain barrier. They are encoded by genes of the solute carrier organic anion 
transporter (SLCO) superfamily, which includes 11 members in humans. The mechanism 
of substrate transport via OATPs is not completely understood. It is, however, believed to 
occur by electroneutral exchange, in which cellular uptake of organic anions is coupled to 
the efflux of neutralizing anions such as bicarbonate, glutathione or glutathione-S-
conjugates (Kim, 2003; Mikkaichi et al., 2004; Niemi, 2007). 
Of the known OATPs in humans, OATP1A2, OATP1B3, OATP4A1, OATP2B1, 
OATP3A1, and OATP1B1 are expressed in the placenta, as summarized in Table 2. 
Expression of OATPs in the human placenta has been investigated (Ugele et al., 2003). 
The authors found OATP2B1 (previously known as OATP-B) to be highly expressed in 
term placental tissue and freshly isolated mononucleated trophoblasts. OATP3A1 (OATP-
D) and OATP4A1 (OATP-E) were highly and equally expressed in term placental tissue 
and in freshly isolated and cultured trophoblasts. Expression of OATP1A2 (OATP-A) was 
low in term placental tissue and freshly isolated mononucleated trophoblasts compared to 
OATP1B1 (OATP-C) whose expression was low in term placental tissue but was not 
detectable in isolated and cultured trophoblasts. OATP1B3 (OATP-8) was intermediately 
expressed in the placental tissue (Ugele et al., 2003).  
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Table 2: Summary of OATP transporters expressed in the placenta 
 
Transporter Expression in: 
i) term placental tissue 
ii) freshly isolated 
mononucleated trophoblasts 
(Ugele et al., 2003) 
Localization Expression in 
the third 
trimester 
compared to 
first trimester 
(Patel et al., 
2003) 
OATP1A2 
(OATP-A) 
Low in both (i) and (ii)  down regulated 
8-fold 
OATP1B3 
(OATP-8) 
Intermediately expressed in (i)   
OATP4A1 
(OATP-E) 
Highly and equally expressed in 
(i) and (ii) 
Apical (Sato 
et al., 2003) 
Not 
differentially 
expressed in the 
two trimesters 
OATP2B1 
(OATP-B) 
High in both (i) and (ii) Basolateral, 
throughout 
the gestation 
(St-Pierre et 
al., 2002) 
 
OATP3A1 
(OATP-D) 
Highly and equally expressed in 
(i) and (ii) 
 down regulated 
17-fold 
OATP1B1 
(OATP-C) 
Low in (i); not detectable in (ii)  Not 
differentially 
expressed in the 
two trimesters 
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St. Pierre et al. showed by Western blotting and immunohistochemistry that 
OATP2B1 was expressed at the basolateral surface of the syncytiotrophoblast throughout 
gestation and was also localized in cytotrophoblasts before differentiation to the 
syncytiotrophoblast (St-Pierre et al., 2002). Western blotting analysis carried out by Sato et 
al. showed a single band for OATP4A1 in the human placenta. In addition, 
immunohistochemsitry revealed that it was predominantly expressed at the apical surface 
of the syncytiotrophoblasts in the placenta, suggesting a functional role for the 
transplacental transfer of thyroid hormone (Sato et al., 2003). Expression of OATP4A1 in 
the placenta is also reported elsewhere, where the authors suggested its importance in 
maternal thyroid hormone transport to the developing fetus (Hagenbuch, 2007). 
Semi-quantitative expression analysis of OATP1A2, OATP1B1, OATP3A1, and 
OATP4A1, along with a few other genes was carried out by Patel et al. in first and third 
trimester human placenta (Patel et al., 2003). Expression of OATP1A2 and OATP3A1 was 
down regulated eight and seventeen fold, respectively, in the third trimester compared to 
the first trimester. In contrast, OATP1B1 and OATP4A1 were not differentially expressed 
in first and third trimester placentae. OATP1B1 gene expression was not detected in the 
third trimester placenta, while low levels of transcripts were detected in the first trimester 
placentae (Patel et al., 2003). Serrano et al. used cytokeratin-7-positive trophoblast cells 
(hTr) isolated from human term placentas and the choriocarcinoma cell lines (hCC) BeWo, 
Jeg-3 and JAr to investigate the expression of OATP2B1, OATP1B3, OATP1A2, and 
OATP1B1, along with other genes (Serrano et al., 2007). In hTr, the expression was high 
for OATP2B1 and OATP1B3, very low for OATP1A2 and not detectable for OATP1B1. 
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Expression patterns in hCC mimicked those in hTr, although the authors did find some 
important cell line-specific differences (Serrano et al., 2007). 
Briz et al. investigated the role of OATPs in the transport of unconjugated bilirubin 
by the placenta-maternal liver tandem (Briz et al., 2003). The authors obtained RNA from 
human liver (hL), human placenta (hPl) at term, and purified cytokeratin-7-positive 
mononucleated human trophoblast cells (hTCs). Using analytical RT-PCR, agarose gel 
electrophoresis separation and sequencing, mRNA of OATP1A2 and OATP1B3 was 
identified in hL, hPl, and hTCs where as that of OATP1B1 was only detectable in hL. 
Real-time quantitative RT-PCR revealed that in hL the abundance of mRNA was 
OATP1B3 > OATP1B1 >> OATP1A2, where as in hPl and hTCs, it was OATP1B3 >> 
OATP1A2 >> OATP1B1. The authors observed the expression levels for these OATPs to 
follow the rank order hL >> hTCs > hPl (Briz et al., 2003). 
 
HIV PROTEASE INHIBITORS AND OATP TRANSPORTERS 
As mentioned earlier, OATPs may have an important role in human drug 
disposition; their presence on the apical and/or basolateral side of the placental 
syncytiotrophoblast may affect the extent to which HIV protease inhibitors get transferred 
across the placenta. HIV protease inhibitors have been shown to be inhibitors of OATP2B1 
in Caco-2 cells (Kis et al., 2008). RT-PCR and immunoblotting was used to determine the 
OATP2B1 mRNA and protein expression in OATP2B1-overexpressing MDCKII and 
Caco-2 cells. The authors screened a number of antiretroviral compounds for inhibition of 
OATP2B1-mediated transport by measuring estrone-3-sulfate in MDCKII/OATP2B1 and 
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Caco-2 cells in the presence or absence of each drug. They also determined the IC50 values 
by performing concentration-dependent inhibition studies. Atazanavir and ritonavir were 
not found to be transported by OATP2B1, along with several other protease inhibitors; 
however, they were potent inhibitors in both cell models. In MDCKII/OATP2B1 cells, the 
IC50 values were 3.9 µM for atazanavir, 2.2 µM for ritonavir, 0.72 µM for lopinavir, 
0.67µM for nelfinavir, and 0.88 µM for tipranavir. The corresponding values in Caco-2 
cells were 2.5 µM, 1.1 µM, 1.7 µM, 1.8 µM, and 0.72µM. The authors did not observe any 
significant inhibition for other classes of antiretrovirals and some protease inhibitors at 
clinically relevant concentrations (Kis et al., 2008). 
In other studies, human OATPs, ABCC, ABCB1 and lipophilicity were important 
determinants of the extent of cellular uptake and retention of saquinavir and lopinavir in 
the used T-cell lines (CEM, CEMVBL, and CEME1000) and in peripheral blood mononuclear 
cells (Janneh et al., 2008). MK571, furosemide (inhibitors of ABCC) and XR9576 
(inhibitor of ABCB1) increased the uptake of both the drugs whereas estrone-3-sulfate 
(hOATP substrate) and montelukast (hOATP inhibitor) reduced the uptake in some but not 
all of the cells (Janneh et al., 2008). Additionally, lopinavir is a substrate of OATP1B1 
(Shallcross et al., 2008a) and OATP1A2 (Shallcross et al., 2008b). 
In a study carried out with saquinavir, Xenopus oocytes injected with OATP1B1 
cRNA demonstrated an approximately 50% increase in the uptake of 14C-saquinavir 
compared to water injected oocytes after 1 hour, and a 2-fold increase after 2 hours 
(Kutscher et al., 2005). In addition, a linear increase in uptake of 14C-saquinavir with time 
was at a significantly greater rate in OATP1B1 injected oocytes compared to water 
 23
   
injected oocytes. This suggested an involvement of OATP1B1 in saquinavir uptake 
(Kutscher et al., 2005). 
Thus, there have been studies that report interaction of protease inhibitors with 
OATPs. With protease inhibitors being substrates of ABC as well as OATP transporters, 
there may be a possibility of interplay between these classes of transporters which would 
affect the extent of drug getting transferred across the placenta. Expression of these 
transporters in the experimental model used and in the individual patients in the clinical 
situation would also play an important role. 
 
PLASMA PROTEIN BINDING ISSUES 
The placenta separates maternal and fetal blood circulations, wherein, the 
concentrations of drug binding proteins are high in both circulations. However, they are 
unequal and dynamic over time. This protein concentration gradient favors partitioning of 
total drug on the maternal side for highly plasma protein bound drugs like HIV protease 
inhibitors (most > 98%). It has been shown that concentrations of plasma proteins such as 
α1-acid glycoprotein and albumin change during the gestation period.  Between 12 and 41 
weeks gestation, maternal serum albumin concentration ranges from 311 µM (20.5 g/L) to 
583 µM (38.5 g/L), while fetal serum albumin ranges from 114 µM (7.5 g/L) to 603 µM 
(39.8 g/L) (Krauer et al., 1984), and as high as 659 µM (43.5 g/L) (Nation, 1981). Maternal 
serum AAG concentration, on the other hand, ranges from 7 µM (0.29 g/L) to 24 µM (1.05 
g/L) (Krauer et al., 1984) and as high as 46 µM (2 g/L) in the presence of acute or chronic 
inflammation (Chu et al., 1981). Fetal serum AAG concentrations range from ≤ 0.2 µM 
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(0.01 g/L) to 9 µM (0.41 g/L) (Krauer et al., 1984). Similar plasma/serum protein 
concentration ranges have been observed in other studies as well (Laurell, 1968; Ganrot, 
1972; Chu et al., 1981; Nation, 1981; Wood and Wood, 1981; Raynes, 1982; Denson et al., 
1984; Krauer et al., 1984).  Thus, the binding of highly plasma protein bound drugs such as 
HIV protease inhibitors, changes during gestation.  
Additionally, because of concentration differences of proteins in the maternal and 
fetal circulations, it is important to determine the unbound fraction of the protease 
inhibitors, not only in the maternal blood but also the fetal/cord blood. Sudhakaran et al 
observed a higher unbound fraction of indinavir and saquinavir in cord plasma compared 
to maternal plasma and suggested this binding differential to be due to the transplacental 
AAG concentration gradient (Sudhakaran et al., 2006). Assuming that the clearance would 
be same in the maternal and fetal compartment, the protein concentration gradient that 
exists in the maternal and fetal circulations during pregnancy may unfavorably affect 
partitioning of the total drug into the fetal compartment, while free drug concentrations 
may be equivalent. 
 
INTRACELLULAR ACCUMULATION OF HIV PROTEASE INHIBITORS 
Intracellular accumulation of HIV protease inhibitors has been investigated and 
marked differences have been observed among them in vitro. Jones et al. used CEM cells 
to study this and found a hierarchy in the intracellular accumulation of four protease 
inhibitors they studied in the rank order nelfinavir > saquinavir > ritonavir > indinavir 
(Jones et al., 2001b). They also used CEM cells treated with vinblastine (CEMVBL) or 
 25
   
epirubicin (CEME1000) that had an increased expression of ABCB1 or ABCC1, 
respectively, to study the effect of active transport on this accumulation. A significant 
reduction in the intracellular accumulation of nelfinavir, saquinavir, and ritonavir in 
CEMVBL cells and of saquinavir and ritonavir in CEME1000 cells was observed. The effect 
of inhibition of active transport was also studied by incubating the cells at 4°C and in the 
presence of 2-deoxyglucose and rotenone. This resulted in a reduction in accumulation of 
saquinavir and ritonavir; however, it had no effect on indinavir accumulation in all cell 
types. For nelfinavir, an increase in accumulation was observed in CEMVBL cells as a result 
of inhibition of active transport. The authors concluded that ABCB1 and ABCC1 along 
with some active influx mechanisms may contribute to the drug accumulation of protease 
inhibitors (Jones et al., 2001b). Meaden et al. investigated whether differences in 
expression of ABCB1 and ABCC1 in human lymphocytes correlated with intracellular 
concentrations of ritonavir and saquinavir (Meaden et al., 2002). The authors determined 
the expression of these transporters in peripheral blood mononuclear cells isolated from 
HIV positive patients and also measured the plasma and intracellular ritonavir and 
saquinavir concentrations. An increased expression of these transporters was associated 
with lower intracellular accumulation of the drugs (Meaden et al., 2002). 
Khoo et al. determined the intracellular accumulation of saquinavir, ritonavir, and 
indinavir in 50 HIV-positive patients (Khoo et al., 2002). The authors collected paired 
plasma and intracellular samples (samples from peripheral blood mononuclear cells) over a 
full dosing interval from patients and expressed the data as intracellular/ plasma drug 
concentration ratios. Similar to previously published results, the authors observed a 
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hierarchy of intracellular accumulation in the rank order saquinavir > ritonavir > indinavir 
(Khoo et al., 2002). The authors also performed the fractionation of U937 cells (human 
leukemic monocyte lymphoma cells) and studied the intracellular localization of the above 
drugs. Efflux kinetics of saquinavir with time and at different temperatures (37°C and 4°C) 
was also studied. It was suggested by the authors that the recovery of protease inhibitors 
associated with the cell pellets represented the drug that was present within the cell 
compartments, such as the cytoplasm and mitochondria, rather than that bound to the cell 
surface membrane. The radiolabelled compounds were detected in all sub-cellular fractions 
(cytosolic, nuclear, heavy and light mitochondrial). Though the authors did not discuss 
this, it seems that the PIs accumulated to a maximum extent in the mitochondrial fractions 
compared to the nuclear or cytosolic fractions. The authors also found the efflux out of the 
cells to be time and temperature dependent (Khoo et al., 2002). 
Mechanisms involved in controlling the intracellular penetration of HIV protease 
inhibitors have been reviewed earlier (Hoggard and Owen, 2003; Ford et al., 2004). The 
authors in these reviews discuss that the plasma drug concentrations of these compounds 
depend on the extensive first pass metabolism which contributes to low and variable 
bioavailability. These drugs are also substrates of several transmembrane uptake (OATP) 
and efflux (ABC) transporters (Hoggard and Owen, 2003; Ford et al., 2004).  
Most of the protease inhibitors are highly plasma protein bound (>95%, except 
indinavir which is 60% bound) and this reduces the fraction of drug available for cell 
penetration or crossing the placenta. These drugs predominantly bind to AAG, which has a 
number of genetic variants and shows variable expression in HIV patients (Boffito et al., 
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2002). Reduced intracellular protease inhibitor concentrations (saquinavir- 31.5 µM to 7.4 
µM, ritonavir- 8.8 µM to 1.6 µM, and indinavir- 3.0 µM to 1.5 µM) have been observed in 
the presence of 2.0 mg/ml AAG (Jones et al., 2001a). However, since protease inhibitors 
are low extraction ratio drugs, a change in unbound fraction of these drugs may not be 
clinically relevant but there will be a change in total drug concentration as well. 
Determination of both total and unbound plasma drug concentrations is, therefore, 
necessary to get a better insight into the drug available for pharmacological effect.  
As the protease inhibitors are highly bound to extracellular proteins, they may also 
be highly bound to intracellular proteins; there are many protein rich areas within the cell 
as well (microfilaments, microtubules, proteins embedded in cellular, nuclear and 
mitochondrial membranes, and phospholipids and proteins in the endoplasmic reticulum). 
The drugs show differential accumulation; mechanisms suggested as mediating these 
intracellular accumulation differences include differences in lipophilicity, intracellular 
protein binding, and ion trapping. These drugs are also substrates of efflux and uptake 
transporters, which may contribute to differences in intracellular accumulation (Hoggard 
and Owen, 2003; Ford et al., 2004). 
 
WHY LOPINAVIR/ RITONAVIR? 
As mentioned earlier, the use of HAART regimens has significantly reduced the 
perinatal transmission to less than 2% (Watts, 2006). It has also been discussed earlier that 
a lower placental transfer of protease inhibitors compared to other antiretrovirals in a 
HAART regimen may result in viral resistance leading to treatment failure.  
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As recently as two years ago, nelfinavir was used as a first line agent in the 
treatment of pregnant HIV infected patients. This was because it was the protease inhibitor 
with the most pharmacokinetic data and clinical experience with use in pregnancy (Watts, 
2006). In 2007, however, the FDA recommended not to offer regimens containing Viracept 
(nelfinavir mesylate) to pregnant women who needed to begin an antiretroviral therapy. As 
a precaution, they also recommended pregnant women receiving Viracept to be switched to 
a therapy consisting of an alternative protease inhibitor. This was because excess levels of 
ethyl methanesulfonate (EMS) were detected in Roche Ltd- manufactured active 
pharmaceutical ingredient of Viracept. Because data from animal studies were available 
that indicated EMS as teratogenic, mutagenic, and a potential human carcinogen; FDA 
recommended pregnant women to limit their exposure to EMS during pregnancy. 
Maintaining the health of the mother and the prevention of viral transmission to the fetus 
were goals of paramount importance 
(http://www.fda.gov/MedWatch/safety/2007/VIRACEPT_HCPLetter_9_10_07.pdf). 
Lopinavir/ritonavir is approved for use in combination antiretroviral therapy for 
HIV infection in adults and children (http://www.rxabbott.com/pdf/kaletratabpi.pdf). 
Ritonavir is used in the combination as a boosting agent that inhibits the CYP3A4 
mediated metabolism of lopinavir providing increased plasma levels of lopinavir. 
Lopinavir/ritonavir is assigned Food and Drug Administration (FDA) Pregnancy Category 
C, indicating that risk to pregnancy cannot be ruled out; adequately powered human 
studies are lacking; and animal studies are either positive for fetal risk or unavailable 
(http://www.rxabbott.com/pdf/kaletratabpi.pdf,http://www.fda.gov/cder/pediatric/21cfr201
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57.htm). In animal studies of lopinavir/ ritonavir, no treatment related malformations were 
reported, however, embryonic developmental toxicities occurred in rats receiving 
maternally toxic doses (http://www.rxabbott.com/pdf/kaletratabpi.pdf). A recent study 
used the Antiretroviral Pregnancy Registry data to estimate the birth defect risk after 
pregnancy exposures to lopinavir/ritonavir (Roberts et al., 2009). The authors did not 
observe a significant difference between the prevalence of birth defects among infants 
prenatally exposed to lopinavir/ritonavir and the internal (first trimester exposures 
compared with combined second/third trimester lopinavir/ ritonavir exposures) or external 
(Metropolitan Atlanta Congenital Defects Program) comparison groups. The data obtained 
in this study has reassured patients and clinicians about the safety of lopinavir/ritonavir in 
the treatment of HIV-positive pregnant women (Roberts et al., 2009). This explains why 
lopinavir/ ritonavir is currently the preferred protease inhibitor recommended by the US 
Department of Health and Human Services for use with other antiretrovirals during 
pregnancy (http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf). As a result, the studies 
presented herein focus on lopinavir. 
 
WHY BeWo CELL LINE AS A MODEL? 
The extent of fetal exposure to a drug can be best studied by carrying out clinical 
studies with pregnant women; however, due to ethical and practical issues concerning 
maternal and fetal health this approach is not used. Also, because of structural and 
physiologic differences between human placenta and placenta of other species, 
extrapolation of data from animal models to humans may not give the actual picture of the 
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mechanisms involved. Several ex vivo and in vitro models are used to study placental 
transfer of compounds, which include perfused placental model, trophoblast tissue 
preparations (villous preparations, and microvillous brush-border membrane and basal 
membrane vesicles), and trophoblast cultures. These techniques have been reviewed well 
in literature (Mitra and Audus, 2008). 
The BeWo cell line is a choriocarcinoma derived cell line that forms polarized, 
confluent monolayers. It is of human origin, is easy to maintain and grows to a confluent 
monolayer in 4-5 days. The cells are polarized with respect to expression of transporters on 
the apical and basolateral membranes and of the enzymes as well. Several ABC and OATP 
transporters are expressed in BeWo cells, as previously discussed. Transport studies can be 
carried out using either transwell inserts or side-by-side diffusion chambers (Mitra and 
Audus, 2008). Also, the BeWo cell line appeared to be a good model of the human 
syncytiotrophoblast and as a result, we chose this cell culture model of the human placental 
trophoblast for our studies. 
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CHAPTER 2 SIGNIFICANCE, HYPOTHESIS  
AND SPECIFIC AIMS 
 
 
HIV is a deadly virus that has infected close to 60 million people since its onset, 
with almost 20 million dying from its complications. Of the more than 40 million people 
with HIV infection today, close to half of them are women, and more than 3 million are 
children under the age of 15 (Libman and Makadon, 2007). Over the past decade, HAART 
has led to a significant increase in life expectancy. In pregnant HIV infected patients, HIV 
may get transmitted from the mother to the fetus. The maximum chance of transmission of 
the virus is at the time of birth through the mucous membranes. HAART serves two goals 
in HIV-infected pregnant patients; providing adequate treatment for the mother and 
preventing viral transmission to the fetus. The use of HAART regimens has led to a 
significant reduction in occurrence of perinatal transmission to less than 2% (Watts, 2006). 
Among the antiretroviral drugs used, there are differences in the extent of transfer of these 
drugs across the placenta; HIV protease inhibitors are particularly poorly transferred. 
The placenta separates maternal and fetal blood circulations, wherein, the 
concentrations of drug binding proteins are high in both circulations. However, they are 
unequal and dynamic over time. This protein concentration gradient favors partitioning of 
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total drug on the maternal side for highly plasma protein bound drugs like HIV protease 
inhibitors (most > 98 %). It has been shown that concentrations of plasma proteins such as 
α1-acid glycoprotein and albumin change during the gestation period (Krauer et al., 1984). 
Thus, the binding of highly plasma protein bound drugs such as HIV protease inhibitors, 
changes during gestation. Additionally, because of concentration differences of proteins in 
the maternal and fetal circulations, it is important to determine the unbound fraction of the 
protease inhibitors, not only in the maternal blood but also the fetal/cord blood. 
One of the major reasons responsible for poor placental transfer of HIV protease 
inhibitors is that they are substrates of ABC transporters present on the maternal side of the 
placental syncytiotrophoblast. These transporters efflux the drugs back into the maternal 
circulation, which may result in failure to prevent vertical transmission. Inhibition of these 
transporters will result in an increase in placental transfer of protease inhibitors. 
Sudhakaran et al. have suggested the use of ABCB1 inhibitors to achieve higher transfer 
across the placenta for drugs which are substrates of ABCB1 (Sudhakaran et al., 2008). 
Among HIV protease inhibitors, saquinavir is the most studied drug. For this study, 
however, lopinavir was chosen as the drug to study as its combination with ritonavir is 
currently the drug combination of choice to treat HIV infected pregnant women. Limited 
data are available for lopinavir. Additionally, protease inhibitors also interact with ABCC1 
(Srinivas et al., 1998) and ABCC2 (Huisman et al., 2002). Therefore, ABCC1 and 
ABCC2, which have not been studied extensively with protease inhibitors, may also be 
involved in the low lopinavir placental transfer. 
 33
   
Among the experimental models available to study transplacental transfer of drugs, 
BeWo cell line is a cell line that is of human placental origin, is easy to grow, the cells 
reach confluence within 4-5 days, and expresses several transporters and enzymes like the 
human placenta. In addition, this cell line has not been used extensively to study 
transplacental transfer of HIV protease inhibitors. 
 
HYPOTHESIS AND SPECIFIC AIMS: 
Inhibiting the placental ABC transporters increases the transfer of HIV protease 
inhibitors in the maternal-to-fetal direction. 
 
As a result, the purpose of this study was: 
1. To determine the unbound fraction of lopinavir in cord blood. 
2. To characterize the kinetics of lopinavir binding to human AAG and HSA and the 
effects of ritonavir. 
3. To characterize lopinavir uptake and efflux in the BeWo cell model. 
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CHAPTER 3 MATERIALS AND METHODS 
 
 
PROTEIN BINDING STUDIES: 
AAG was obtained from Fisher Scientific (catalog number ICN15390510) and 
from Sigma Aldrich (catalog numbers G9885-10MG and G9885-25MG). HSA was 
obtained from Fisher Scientific (catalog number ICN823234). Lopinavir and 3H-lopinavir 
(specific activity of 100-139 mCi/mmol) were obtained from AK Scientific, CA (catalog 
number 69314) and Moravek Biochemicals, CA (catalog number MT 1648), respectively. 
Ritonavir was obtained from Sigma Aldrich (catalog number R535000) and Bosche 
Scientific, NJ (catalog number R1692). 
Purity of 3H-lopinavir was tested using HPLC. The analysis was done using an 
Alltima C18 column with UV detection at 254 nm. The mobile phase consisted of 100% 
acetonitrile-1% acetic acid in water (55:45 v/v). 50 µL of a 0.01 µCi/µL solution of 
3H-lopinavir in mobile phase was injected into the system. A single peak of lopinavir was 
detected at a retention time of 4.3 minutes and the purity of 3H-lopinavir was 96.1%. 
Placentae were obtained from 4 women (clinical data of the patients shown in 
Table 3) from cesarean section deliveries following normal pregnancies at the VCU 
Medical Center Hospital. The study was approved by the VCU Institutional Review Board 
(protocol #4212 – Appendix I) and informed consent was obtained from patients prior to 
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delivery. Patients with hypertension, diabetes, preeclampsia, HIV infection or febrile 
illness; history of smoking, alcohol or drug abuse were excluded. Maternal blood samples 
were not available in this study.  Cord blood was obtained from placentae within 30 
minutes of birth, allowed to clot on ice, and centrifuged to obtain serum. Maternal serum 
samples were purchased from BioChemed Services (Winchester, VA). These samples were 
obtained from non-smoking pregnant patients aged 19-34 years between 17 and 27 weeks 
gestation (Table 4). Body mass index (BMI) was calculated for each of these pregnant 
patients. The website used to calculate BMI is http://www.nhlbisupport.com/bmi/. 
Rapid equilibrium dialysis (RED, Figure 1; Pierce No. 89809), with a molecular 
weight cut-off of 8,000 Daltons, was used to determine the protein binding of lopinavir in 
maternal serum and in serum obtained from cord blood. These protein binding experiments 
with serum samples were followed by experiments with varying concentrations of 
lopinavir, AAG and HSA. The protein solutions were prepared in phosphate buffered 
saline, pH 7.4 (PBS). The final concentrations of lopinavir were 0.1, 0.32, 1, 3, 10, 30, and 
100 µM. Protein binding of lopinavir was determined in the presence of 7 µM (0.3 g/L) 
and 23 µM (1.0 g/L) AAG, and 15 µM (1 g/L), 152 µM (10 g/L), and 758 µM (50 g/L) 
HSA. 
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Table 3: Clinical data for patients undergoing C-section delivery following normal 
pregnancy 
 
Patient Age 
(years) 
Gestational 
Age 
(Weeks/Days) 
Race Placental 
Weight 
(g) 
Cord serum 
experiments 
Tissue 
binding 
experiments 
4212-
034 
36 39/1 Hispanic 786  X 
4212-
036 
23 39/2 African 
American
839 X  
4212-
037 
23 39/0 White 822 X  
4212-
038 
45 38/3 African 
American
567 X X 
4212-
040 
25 39/0 African 
American
868 X X 
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The protein solution (500 µl) or maternal serum (200 µl) containing the drug was 
added to the sample (inner) chamber and 750 µl of PBS (or 350 µl for maternal serum 
experiments) was added in the buffer (outer) chamber. Non-specific binding was 
determined by adding PBS in both the compartments with the solution in the sample 
chamber containing 3H-lopinavir alone. The Teflon base plate containing the inserts was 
covered and incubated at 37ºC on an orbital shaker at 100 rpm. Samples (50 µl for serum 
experiments and 100 µl for the other experiments) were removed from each side at various 
times up to 16 hours, and 3H-lopinavir in sample and buffer compartments was detected by 
liquid scintillation counting on a Packard TR2800 scintillation analyzer (Perkin Elmer). 
Fraction unbound was determined by taking the ratio of mass of radioactivity observed in 
the buffer chamber to that in the sample chamber. All determinations were made in 
triplicates. 
The equation for drug binding to a protein is given by: 
][+
][
= Lopinavir fK D
Lopinavir fN
PT
B
            Equation (1) 
where, B is the bound drug concentration, PT is the total protein concentration, N is the 
number of binding sites per protein molecule, KD is the equilibrium dissociation constant 
and [Lopinavir]f is the free drug concentration. Binding parameters N and KD were 
determined by non-linear least-squares regression using equation 1 (GraphPad Prism 
version 5). 
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Figure 1: Rapid Equilibrium Dialysis (modified version; original source: 
http://www.piercenet.com/Products/Browse.cfm?fldID=8C6CA217-75C3-4019-AE9C-
D48FF4C00EC6). 
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RED Insert
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These studies were followed by selecting a physiologic maternal concentration of 
AAG (9 µM = 0.38 g/L) or HSA (530 µM = 35 g/L), and carrying out the determination of 
lopinavir protein binding at lopinavir concentrations ranging from 0.1 to 30 µM in the 
presence of different concentrations (0, 1, 10, 25, and 50 µM) of ritonavir. Lopinavir 
protein binding to HSA (530 µM = 35 g/L) was also determined in the presence of a higher 
ritonavir concentration of 100 µM.  Data from HSA and AAG experiments were analyzed 
by two-way ANOVA with Bonferroni’s post-test; significance was assessed at p<0.05. 
Binding of lopinavir in cord and maternal serum was compared using an unpaired t-test 
with Welch’s correction (GraphPad Prism version 5). 
 
BeWo CELL CULTURE STUDIES: 
The BeWo cell line is originally derived from a human choriocarcinoma. The 
BeWo cell line (Schwartz clone; passage 30) was obtained from Dr. Kenneth L. Audus 
(The University of Kansas Medical Center, Kansas City, KS). BeWo cells in these studies 
were used between passages 36-64. 
 
Cell culture medium:  
This was prepared using Dulbecco’s modified Eagle’s medium (DMEM) (high 
glucose with 4500 mg/L glucose and L-glutamine, without sodium bicarbonate, powder, 
cell culture tested; Sigma Aldrich, catalog number D5648-10X1L), fetal bovine serum 
(FBS) (heat inactivated, Quality Biological Inc., catalog number QBI110001101HI), L-
glutamine (200 mM solution; Fisher, catalog number MT25005CIRF), penicillin/ 
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streptomycin (10,000 U/mL; Invitrogen, catalog number 15140122, Quality Biological 
Inc., catalog number QBI120095061) and MEM nonessential amino acids (100x solution; 
Fisher, catalog number MT25025CIRF). 
To prepare the media, protocol described previously (Bode et al., 2006) was 
followed and the steps are explained in brief in Appendix II. 
 
Culturing of BeWo cells: 
10X PBS, pH 7.4 was obtained from Quality Biological Inc. (catalog number 
QBI119069101). 10X trypsin and trypan blue were obtained from Invitrogen (catalog 
number 15400054) and Sigma Aldrich (catalog number T8154-100mL), respectively. 
BeWo cells were grown and cultured according to the protocol previously 
described (Bode et al., 2006), except for a few minor modifications, which are described in 
Appendix II. 
 
Growth of BeWo cells on standard cell culture plates: 
1. The cell pellet was obtained from trypsinization of a 150 cm2 flask. 
2. The supernatant media was aspirated and the cell pellet was resuspended in 10 mL 
of the medium. 
3. After seeding part of this cell suspension to one or more 150 cm2 flasks, additional 
medium was added to the remaining cell suspension so as to come up with a total 
volume of cell suspension enough for the required number of 12 well plates. 1 mL 
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of the cell suspension was seeded to each well of a 12-well plate, which was shook 
to evenly distribute the cells. 
4. The cells were fed every other day subsequently and the uptake/efflux experiments 
carried out when the cells were at least 90-95% confluent, which usually occurred 
4-5 days after plating. 
 
Efflux experiments: 
Preliminary time course experiments: 
After the BeWo cells grown on standard 12-well plates reached 90-95% 
confluence, efflux experiments were carried out to determine the efflux of 3H-lopinavir 
from BeWo cells in the presence and absence of different inhibitors of ABC transporters 
present on the maternal side of the placental syncytiotrophoblast. The media was aspirated 
and the cells were washed once with Dulbecco’s Phosphate Buffered Saline (DPBS). The 
cells were then incubated for 30 minutes with DPBS. The buffer was aspirated after 30 
minutes and replaced by the uptake buffer which consisted of 3H-lopinavir (0.32 µM) in 
DPBS ± any inhibitors of ABC transporters. Verapamil, a known ABCB1 inhibitor, or 
sodium orthovanadate, an inhibitor known to inhibit all ATP dependent processes, were 
used at concentrations of 100 µM or 500 µM, respectively. There was a one hour pre-
incubation period with 1 mM sodium orthovanadate for the experiment with sodium 
orthovanadate. The inhibitors were added at the uptake step so that the cells are 
equilibrated with the inhibitor before the efflux step. In the later experiments, however, the 
inhibitors were not included at the uptake step. The cells were incubated with the uptake 
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buffer for 5 minutes. The entire buffer solution was aspirated after 5 minutes and the cells 
were then incubated with the efflux buffer which comprised of inhibitor solutions in DPBS 
for various time intervals (0 min, 2 min, 5 min, 10 min, or 20 min). The entire buffer 
solutions were then collected and the samples were analyzed by mixing 5 mL of 
scintillation cocktail and counting on a Liquid Scintillation Analyzer (Tri-Carb 2800TR, 
Perkin Elmer). To each well of the 12-well plate, 1 mL of lysis buffer (0.5% Triton X-100 
in 0.2 N NaOH) was then added. The plate was covered and incubated in the incubator at 
37°C for 2 hours, or at 4°C overnight. After the incubation period, entire contents of each 
well (~ 1-1.2 mL) were mixed by pipetting and collected in different scintillation vials. 
Scintillation cocktail (5mL) was then added to the samples which were then analyzed by 
liquid scintillation counting. 
 An efflux experiment was also done in the presence or absence of verapamil 
(100µM) without any cells on the plate. This was done to determine any non-specific 
binding of 3H-lopinavir to the plastic. 
An efflux experiment was also done in the presence or absence of GF120918 
(1µM, known ABCB1 inhibitor) and ritonavir (10 µM). Ritonavir was used since its 
combination with lopinavir is used clinically to treat HIV-infected pregnant patients. 
 
Efflux experiments at 37°C and 4°C: 
Efflux experiments with 3H-lopinavir (0.32 µM) and verapamil (100 µM) were also 
performed at different temperatures to differentiate between the uptake and binding 
components of lopinavir transport across the BeWo cells. The only difference between 
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these and earlier timed experiments was that these experiments were done by incubating 
the cells at different temperatures (37°C and 4°C) for 5 or 10 minutes in the uptake step 
followed by a 20 minute efflux step. 
 
Obtaining cell pellets for cell pellet binding experiments: 
1. The cell pellet was obtained from trypsinization of a 150 cm2 flask. 
2. The supernatant media was aspirated and the cell pellet was resuspended in 10 mL 
of the medium. 
3. After seeding part of this cell suspension to one or more 150 cm2 flasks, the 
remaining cell suspension was centrifuged again to pellet at 300 G for 8 minutes at 
room temperature. 
4. The cell pellet was uniformly resuspended in 1 mL of medium and the entire cell 
suspension was transferred to a pre-labeled eppendorf tube. The cells in the tube 
were then stored at -80°C for cell pellet binding experiments. 
 
BeWo cell and placental tissue homogenate binding experiments with 3H-lopinavir: 
3H-lopinavir binding to the placental tissue was determined using the RED device. 
Approximately 500 mg of placental tissue (patient numbers 4212-034, -038, and -040) 
frozen previously at -80°C was homogenized in PBS (3 mL). 500 µL of this homogenized 
tissue from each patient containing 3H-lopinavir (0.64 µL of 0.025 µCi/µL) was transferred 
in triplicate to the sample (inner) chamber of the RED inserts. PBS (750µL) was added to 
the buffer (outer) chamber and the Teflon base plate containing the inserts was covered and 
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incubated at 37°C on an orbital shaker at 100 rpm. Samples (100 µL) were collected at the 
end of 16 hours, and 3H-lopinavir in sample and buffer compartments was detected by 
liquid scintillation counting. Fraction unbound was determined as previously. The 
remaining placental tissue homogenate was used to determine the protein content using the 
Lowry protein assay (Appendix III). 
A similar experiment was also carried out with BeWo cell pellets stored at -80°C 
(cell pellets from passage numbers 34, 39, 40, 41, 43, and 45). The cell suspensions in 
DMEM stored at -80°C were centrifuged at 300 G (approx. 2000 rpms) for 8 minutes at 
4°C using Microfuge 18 Centrifuge (Beckman Coulter). The pellets obtained were 
resuspended in DPBS without Ca/Mg (4°C) and centrifuged again at 2000 rpms for 8 min 
at 4°C. This was done twice before resuspending the pellets in 1 mL PBS (4°C). The cell 
suspensions obtained from the above step were then pooled together and transferred to a 
14mL Falcon 2059 tube. EDTA was added to the cell suspension (to provide 1 mM 
EDTA) along with protease inhibitor cocktail (240 µL of 1 tablet/ 2 mL solution in water). 
This pooled cell suspension was homogenized on ice and was used to carry out the cell 
homogenate binding experiments at 37°C and 4°C in the presence or absence of verapamil 
(100 µM) or ritonavir (10 µM). The remaining suspension was also used to determine the 
protein content using the Lowry protein assay (Appendix III). 
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Uptake experiments: 
Preliminary time course experiments: 
After the BeWo cells grown on standard 12-well plates reached 90-95% 
confluence, uptake experiments were carried out to determine the uptake of 3H-lopinavir in 
BeWo cells in the presence and absence of different inhibitors of ABC transporters present 
on the maternal side of the placental syncytiotrophoblast. These experiments were carried 
out in a similar way, until the addition of the uptake buffers, as the preliminary time course 
efflux experiments. The cells were incubated with the uptake buffer for various time 
intervals (0 min, 2 min, 5 min, 10 min, or 20 min). The entire buffer solutions were 
collected and the samples were analyzed by mixing 5 mL of scintillation cocktail and 
counting on a Liquid Scintillation Analyzer (Tri-Carb 2800TR, Perkin Elmer). To each 
well of the 12-well plate, 1 mL of lysis buffer comprising of 0.5% Triton X-100 in 0.2 N 
NaOH was added. The plate was covered and incubated in the incubator at 37°C for 2 
hours, or at 4°C overnight. After the incubation period, the contents of each well were 
mixed by pipetting and collected in different scintillation vials. Scintillation cocktail (5mL) 
was added to the samples which were then analyzed by liquid scintillation counting. 
 
Uptake experiments at 37°C and 4°C: 
Uptake experiments with 3H-lopinavir (0.32 µM) and verapamil (100 µM) were 
also performed at different temperatures to differentiate between the uptake and binding 
components of lopinavir transport across the BeWo cells. The only difference between 
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these and earlier timed experiments was that these experiments were done by incubating 
the cells at different temperatures (37°C and 4°C) for 10 minutes. 
 An uptake experiment at 37°C was also done in the presence of 
bromosulfophthalein (BSP, 50 µM) and taurocholate (TC, 100 µM) as inhibitors of certain 
OATP transporters. Trans-stimulation was determined by pre-loading cells with TC, and 
removing TC from the 3H-lopinavir loading buffer. Cis-inhibition was determined for BSP 
and TC by adding them with 3H-lopinavir to the loading buffer. 
 
Statistical analysis: 
Two-way ANOVA was used to compare the uptake of 3H-lopinavir in the presence 
or absence of inhibitors of ABC transporters at various time intervals. It was also used to 
compare the same in the efflux experiments. Two-way ANOVA was also used to compare 
unbound fraction of 3H-lopinavir in the presence or absence of verapamil or ritonavir at 
37°C and 4°C (GraphPad Prism version 5). 
The uptake or efflux of 3H-lopinavir in the presence or absence of verapamil at 
37°C or 4°C was also analyzed using a two-way ANOVA, which was followed by 
Bonferroni post-tests pairwise comparisons. Efflux of 3H-lopinavir in the presence or 
absence of GF120918 or ritonavir; and uptake of 3H-lopinavir in the presence or absence of 
BSP or TC were analyzed by one-way ANOVA with Dunnett’s post test (GraphPad Prism 
version-5). All results are presented as mean ± standard deviation. P-value of 0.05 or less 
was considered to indicate a statistically significant difference.
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CHAPTER 4 RESULTS AND DISCUSSION 
 
 
PROTEIN BINDING STUDIES: 
Protein binding equilibrium was achieved within 16 hours (Figure 2), and non-
specific binding was negligible. Fraction unbound for lopinavir in serum obtained from 
cord blood from term placentae of healthy patients was 0.022 ± 0.011 (mean ± SD, n = 4). 
The results are similar to unpublished data of Else et al. (0.017 ± 0.010) who reported the 
protein binding of lopinavir in plasma from cord blood of HIV positive pregnant women at 
term and on lopinavir/ ritonavir therapy (Else et al., 2007). Fraction unbound for lopinavir 
in maternal serum samples was 0.0089 ± 0.0012 (mean ± SD, n = 4), which was not 
significantly different from that observed with cord serum obtained from term placentae 
(p= 0.099). Notably, the variances were significantly different (p < 0.01), which may imply 
more variability in unbound fraction of lopinavir in cord blood. Mean of the fraction 
unbound determined in triplicate for each of the maternal samples has been tabulated with 
the patients' clinical data (Table 4). The unbound fraction of 3H-lopinavir did not correlate 
with the patients' calculated BMIs (p= 0.087). 
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Figure 2: Cord serum binding experiments to determine the time to equilibrium for 3H-
lopinavir. Patients 1, 2 and 3 correspond to patients 4212-036, -037 and -038, respectively. 
Data are presented as mean ± standard deviation. 
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Table 4: Summary of the clinical data of the pregnant patients with their individual mean 
unbound fraction of 3H-lopinavir. Data are presented as mean ± SD. 
 
Lot 
number 
Age 
(years) 
Gestational 
Week 
Race Weight 
(pounds) 
Height BMI Fraction 
Unbound for 
3H-lopinavir 
BC03-
122 
32 17 Asian 175 5'5" 29.1 0.0077 ± 
0.0015 
BC03-
151 
31 27 Caucasian 142 5'3" 25.2 0.0106 ± 
0.0011 
BC03-
182 
34 27 African 
American 
266 5'8" 40.4 0.0084 ± 
0.0011 
BC03-
187 
19 19 African 
American 
147 5'5" 24.5 0.0090 ± 
0.0003 
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Initial experiments with lopinavir and AAG showed AAG-concentration dependent 
lopinavir binding, which was consistent with saturability. Experiments with lopinavir and 
bovine serum albumin (BSA) showed a BSA-concentration dependent lopinavir binding. It 
was observed that lopinavir was appreciably bound to BSA as well as AAG. However, 
these initial pilot studies indicated that further studies would have to be carried out with 
HSA using even wider range of lopinavir and protein concentrations, probably lower HSA 
concentrations in order to obtain estimates of protein binding kinetic parameters. 
Lopinavir binding to 7 µM (0.3 g/L) and 23 µM (1.0 g/L) AAG at varying drug 
concentrations (0.1-30µM) is shown in Figure 3. The binding of lopinavir to AAG was 
dependent on protein and drug concentrations. Fraction bound varied from 0.59 ± 0.03 to 
0.27 ± 0.01 at 7 µM (0.3 g/L) AAG and from 0.87 ± 0.01 to 0.62 ± 0.03 at 23 µM (1.0 g/L) 
AAG over a lopinavir concentration range of 0.1-30 µM. It was not possible to determine 
the binding of lopinavir at 100 µM due to the low solubility of lopinavir. The data obtained 
for binding of lopinavir at both AAG concentrations were simultaneously fit to Equation 
(1) with weighting (1/y2). Figure 4 shows the saturation binding curve of lopinavir at 7 µM 
(0.3 g/L) and 23 µM (1.0 g/L) AAG concentrations in triplicate determinations. KD was 5.0 
± 1.1 µM and N was 1.2 ± 0.2. Binding of lopinavir to AAG thus appeared saturable. 
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Figure 3: Lopinavir binding to AAG: Lopinavir binding at varying drug concentrations 
(0.1-30 µM) to 7 µM AAG (z) and at 0.1-100 µM to 23 µM AAG (). Data are presented 
as mean ± standard deviation. 
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Figure 4: Lopinavir binding to AAG: Bound lopinavir concentrations normalized for 
AAG concentration as a function of unbound lopinavir concentrations. AAG: 7 µM (z); 
23 µM (). Data are presented as mean ± standard deviation. 
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Similar triplicate experiments were carried out at several HSA concentrations (15, 
152, or 758 µM; equal to 1.0, 10.0, or 50.0 g/L, respectively). Lopinavir binding to 15, 152 
and 758 µM (1.0, 10.0 and 50.0 g/L, respectively) HSA at varying drug concentrations 
(0.1-100 µM) is shown in Figure 5. In contrast to binding of lopinavir to AAG, binding to 
HSA was less dependent on lopinavir concentration; however, binding was dependent 
upon HSA concentration. With HSA, fraction bound ranged from 0.41 ± 0.06 to 0.29 ± 
0.06 over a lopinavir concentration range of 0.1-30 µM at 15 µM (1.0 g/L) HSA and from 
0.90 ± 0.01 to 0.81 ± 0.02 over a lopinavir concentration range of 0.1-100 µM at 152 µM 
(10.0 g/L) HSA. It was not possible to determine the binding of lopinavir at 100 µM in the 
presence of a low HSA concentration (15 µM = 1.0 g/L) due to the low solubility of 
lopinavir. At 758 µM (50.0 g/L) HSA, fraction bound of lopinavir (0.96 ± 0.02) was 
independent of lopinavir concentration (0.1-100 µM). The data obtained for binding of 
lopinavir to varying HSA concentrations were also simultaneously fit to Equation (1) with 
weighting (1/y2). Figure 6 shows the saturation binding curve of lopinavir at 15, 152, and 
758 µM (equal to 1.0, 10.0, and 50.0 g/L) HSA concentrations. KD was estimated to be 
24.3 ± 8.7 µM and N was 1.1 ± 0.4. However, at a physiologic concentration of 758 µM 
(50.0 g/L) HSA, lopinavir binding was essentially non-saturable. 
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Figure 5: Lopinavir binding to HSA: Lopinavir binding at varying drug concentrations 
(0.1-30 µM) to 15 µM HSA (z), and at 0.1-100 µM lopinavir to 152 µM () and 758 µM 
HSA (▲). Data are presented as mean ± standard deviation. 
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Figure 6: Lopinavir binding to HSA: Bound lopinavir concentrations normalized for 
HSA concentration as a function of unbound lopinavir concentrations. HSA: 15 µM (z); 
152 µM (); 758 µM (▲). Data are presented as mean ± standard deviation. 
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The KD values obtained in the case of experiments with AAG and HSA can be 
compared to the therapeutic concentrations of lopinavir to determine if the binding is 
saturable or non-saturable. Lopinavir Cmax following administration of 400 mg lopinavir 
with 100 mg ritonavir to healthy male volunteers is 13.5 µM 
(http://www.fda.gov/cder/foi/nda/2000/21-226_Kaletra_biopharmr_P1.pdf). However, the 
estimated unbound lopinavir concentration would be approximately 0.2 µM. According to 
the results obtained above, KD for lopinavir binding to AAG and HSA of 5.0 ± 1.1 µM and 
24.3 ± 8.7 µM, respectively, were much higher than the estimated unbound lopinavir 
concentration. Thus, lopinavir binding to both AAG and HSA would be non-saturable at 
therapeutic concentrations. 
 The data indicate that binding to HSA and AAG can account for the total protein 
binding of lopinavir by multiplying the expected unbound fractions of lopinavir at those 
protein concentrations. For the AAG and HSA concentration ranges previously discussed, 
the predicted lopinavir protein binding would vary between 0.96-0.99 in the maternal 
serum and 0.86-0.98 in the fetal serum during the course of pregnancy, as protein 
concentrations in maternal and fetal serum change between 12 and 41 weeks gestation. The 
range of these predictions includes our observed unbound fractions in both fetal and 
maternal serum. The trend in the present results toward a higher unbound fraction for 
lopinavir in fetal serum is consistent with the higher unbound fraction in cord blood 
reported for indinavir and saquinavir (Sudhakaran et al., 2007).  
The results show that protein binding of lopinavir is characterized by saturable 
binding to AAG and non-saturable binding to albumin at physiologic protein 
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concentrations. Although HSA binds lopinavir with a somewhat lower affinity and both 
proteins appear to bind lopinavir at a single site, the physiologic concentration of HSA is 
much greater resulting in a much higher binding capacity. As a result, HSA would 
contribute more to the high degree of total plasma protein binding of lopinavir.   
 
Effect of ritonavir on lopinavir binding to AAG and HSA 
Figure 7 shows the lopinavir binding to 9 µM (0.38 g/L) AAG at various lopinavir 
concentrations (0.1-30 µM) in the presence of ritonavir (0, 1, 10, 25, or 50 µM). Lopinavir 
binding to AAG was significantly displaced by ritonavir only at 50 µM but not lower 
concentrations; it was not possible to obtain a reliable estimate of Ki. Figure 8 shows 
lopinavir binding to 530 µM (35 g/L) HSA at various lopinavir concentrations (0.1-30 µM) 
in the presence of ritonavir (0, 1, 10, or 100 µM). Ritonavir (1, 10 µM) had no apparent 
effect on unbound fraction of lopinavir in the presence of 530 µM (35 g/L) HSA. Only in 
the presence of 100 µM ritonavir (but not lower concentrations), lopinavir binding to HSA 
was significantly altered. 
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Figure 7: Effect of ritonavir on lopinavir binding to AAG: Lopinavir binding to 9 µM 
AAG at various concentrations of lopinavir (0.1-30 µM) in the presence of ritonavir (0, 1, 
10, 25, or 50 µM; z, {, , , ▲, respectively). Data are presented as mean ± standard 
deviation and were analyzed by ANOVA with Dunnett’s post-test (p < 0.05). 
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Figure 8: Effect of ritonavir on lopinavir binding to HSA: Lopinavir binding to 530 µM 
HSA at various concentrations of lopinavir (0.1-30 µM) in the presence of ritonavir (0, 1, 
10, or 100 µM; z, {, , , respectively). Data are presented as mean ± standard 
deviation and were analyzed by ANOVA with Dunnett’s post-test (p < 0.05). 
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Therefore, ritonavir which is co-administered with lopinavir to HIV infected 
pregnant women may not act to displace lopinavir from binding to AAG or HSA at its 
therapeutically relevant concentrations (Cmax = 0.83 µM, Ctrough = 0.30 µM) (Murphy et al., 
2001). 
 
BeWo CELL CULTURE STUDIES: 
There were many preliminary time course uptake as well as efflux experiments that 
were performed with 3H-lopinavir using the BeWo cell line. The results are in Appendix 
IV. The results consistently suggested that verapamil (100 µM) either inhibited the uptake 
of 3H-lopinavir (0.32 µM) or stimulated its efflux. However, some technical issues (cells 
not washed before adding the lysis buffer, stock buffers not analyzed) may hinder the 
interpretation of these results, and the preliminary results have therefore been included as 
an appendix. 
Because there was significantly higher 3H-lopinavir observed in the stock solution 
with sodium orthovanadate compared to the stock without sodium orthovanadate (results in 
Appendix IV), there was a possibility of non-specific binding of 3H-lopinavir to the plastic, 
which may have been displaced by sodium orthovanadate. To confirm these results, an 
experiment on 12-well plates without the cells was carried out with 3H-lopinavir (0.32 µM) 
± verapamil (100 µM). It was observed that almost 10-times as much 3H-lopinavir stuck to 
the plate in the absence of verapamil (28 ± 6 pmols) compared to that in the presence of 
verapamil (3 ± 1 pmols). Therefore, it was concluded that 3H-lopinavir significantly binds 
to plastic and verapamil displaces it from these non-specific binding sites. 
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As lopinavir is a highly plasma protein bound drug, binding experiments using 
RED were carried out to determine lopinavir binding to placental tissue and BeWo cell 
pellets. Placental tissue from pregnant women (patients 4212-034, -038, and -040) was 
homogenized in triplicate to determine any lopinavir binding to the placental tissue. At an 
average protein concentration of 13 g/L, mean fraction bound of 3H-lopinavir (0.32 µM) to 
the tissue homogenates was 0.86 ± 0.03. Interestingly, these results correlated well with the 
3H-lopinavir protein binding observed with HSA, in which fraction bound of 3H-lopinavir 
in the presence of 10 g/L HSA was 0.90 ± 0.01 to 0.81 ± 0.02 over a lopinavir 
concentration range of 0.1-100 µM. Similarly, binding experiments with BeWo cell 
homogenates showed that 3H-lopinavir is considerably bound to the cell homogenate as 
well. 3H-lopinavir binding with the cell pellet homogenate was 0.77 ± 0.04 with the protein 
content estimated to be 3.57 g/L. Extrapolating these results to binding at approximately 10 
times higher protein content, the unbound fraction of 3H-lopinavir would be around 0.023, 
which is similar to that observed with cord serum samples (0.022 ± 0.011). 
Because lopinavir binds non-specifically to plastic, BeWo cells, and also to the 
placental tissue, we added a low concentration of BSA (0.05 %) during the experiments 
with 3H-lopinavir and the inhibitors of ABC transporters to decrease non-specific binding 
and to get a better estimate of 3H-lopinavir being taken into the cells and effluxed out of 
the cells. But the question was where to include 0.05% BSA during the experiments. Two 
separate efflux experiments without the BeWo cells were carried out to answer this 
question and to determine any effect of including BSA on lopinavir sticking to the plate. 
3H-lopinavir (0.32µM) efflux was studied as previously in the presence or absence of 
 62
   
verapamil (100µM), with 0.05% BSA either in the 3H-lopinavir ± verapamil stock 
solutions or in the pre-incubation buffer. The results of these experiments indicated that 
almost 16 times as much 3H-lopinavir still stuck to the plate in the absence of verapamil 
when BSA was included in the stock solutions. In contrast, BSA in the pre-incubation 
buffer caused the 3H-lopinavir concentration to be almost equal in the two stock solutions. 
Therefore, it seemed like a pre-incubation step in the presence of 0.05% BSA was 
necessary to limit non-specific binding in order to better compare 3H-lopinavir transport in 
the presence or absence of verapamil or any other inhibitor. 
Therefore, based on the above experiments and results obtained, following 
conditions were thought to be critical while carrying out experiments with 3H-lopinavir: 
• BSA (0.05%) should be present throughout the experiments, including the pre-
incubation buffers, washing buffers and the stock solutions. 
• Stock solutions of 3H-lopinavir should be prepared in glass tubes so as to avoid its 
non-specific binding to plastic. 
• No verapamil or any other inhibitor should be present at the uptake step in an efflux 
experiment to differentiate between uptake and efflux processes. 
• BeWo cells should be washed at least twice with ice-cold buffer containing 0.05% 
BSA before adding the lysis buffer in an uptake experiment. In an efflux 
experiment, cells should be washed with ice-cold buffer at least twice after the 
uptake step and again twice after the efflux step before adding the lysis buffer. 
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Experiments to differentiate between uptake and binding: 
To differentiate between binding and uptake issues, further uptake and efflux 
experiments were carried out at 37°C and at 4°C, assuming that the transport processes at 
4°C would be inhibited and therefore, would help to differentiate between uptake and 
binding processes. The experiments were carried out as mentioned above, but at two 
temperatures with control and verapamil treated groups. 
 
Efflux of 3H-lopinavir in BeWo cells: 
Next, an efflux experiment with 3H-lopinavir (0.32 µM) and verapamil (100 µM) 
was carried out and the results obtained are presented in Figure 9. A significantly higher 
3H-lopinavir buffer/cell ratio at 37°C in the presence of verapamil shows a stimulation of 
3H-lopinavir efflux. This stimulation of 3H-lopinavir efflux observed instead of inhibition 
by verapamil may be due to ABCC2-mediated transport stimulation in the presence of 
GSH. This stimulation of ABCC2-mediated efflux by verapamil in the presence of GSH 
has been reported earlier (Vaidya et al., 2009). However, expression of ABCC2 in BeWo 
cells is low (Pascolo et al., 2003; Evseenko et al., 2006b), and thus, indicates a possible 
involvement of a different transporter in lopinavir efflux. The apparent increase in 
3H-lopinavir buffer/cell ratio at 37°C in the presence of verapamil would also include any 
intracellular 3H-lopinavir binding displacement caused by verapamil. 
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Figure 9: Efflux of 3H-lopinavir (0.32 µM) in the presence or absence of verapamil 
(100µM) at 37°C or 4°C. Results are presented as mean ± standard deviation and were 
analyzed using two-way ANOVA followed by Bonferroni post-tests pairwise comparisons. 
Asterisks indicate significant difference (p < 0.05); “ns” indicates that the comparison was 
not significant. 
 
C)°
co
ntr
ol 
(37
C)°
ve
rap
am
il (
37
C)°
co
ntr
ol 
(4
C)°
ve
rap
am
il (
4
0
2
4
6
8
10
*
*
*
ns
3 H
-L
op
in
av
ir 
Bu
ffe
r/ 
C
el
l R
at
io
 
 
 
 65
   
A significantly lower 3H-lopinavir buffer/cell ratio in the control group at 4°C compared to 
that observed in the control group at 37°C indicates a temperature-sensitive efflux process. 
A significantly lower 3H-lopinavir buffer/cell ratio at 4°C compared to that observed at 
37°C in the verapamil-treated groups also indicates a temperature-sensitive efflux process. 
In addition, at 4°C, there was no significant difference between the control and verapamil-
treated groups, consistent with minimal intracellular binding displacement by verapamil. 
An efflux experiment at 37°C with GF120918 (1 µM), a known ABCB1 inhibitor 
and with ritonavir (10 µM), known ABCB1, ABCC1, and ABCC2 substrate was carried 
out and the results are shown in Figure 10. There was a significant increase in 3H-lopinavir 
buffer/cell ratio in the presence of ritonavir which suggests either inhibition of uptake or 
stimulation of efflux by ritonavir. Another possibility is an increase in unbound fraction of 
lopinavir in the cell by intracellular binding displacement which may have caused an 
increase in the free drug being effluxed out of the cell. There was no significant difference 
observed between 3H-lopinavir buffer/cell ratio in the presence or absence of GF120918 at 
an effective concentration for selectively inhibiting ABCB1 (Matsson et al., 2009), 
suggesting either the lack of ABCB1 expression in BeWo cells or its lack of activity on 
lopinavir efflux. Other studies in our lab suggest the lack of ABCB1 expression in our 
BeWo cells (Drew Landsberg, unpublished data). 
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Figure 10: Efflux of 3H-lopinavir (0.32 µM) in the presence or absence of GF120918 
(1µM) or ritonavir (10 µM). Results are presented as mean ± standard deviation and were 
analyzed using one-way ANOVA followed by Dunnett’s post-test. Asterisk indicates 
significant difference (p < 0.05); “ns” indicates that the comparison was not significant. 
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Binding of 3H-lopinavir in BeWo cells: 
To determine intracellular binding displacement of 3H-lopinavir by verapamil or 
ritonavir, and the effects of temperature, a BeWo cell pellet binding experiment was done 
with 3H-lopinavir in the presence or absence of verapamil (100 µM) or ritonavir (10 µM), 
as shown in Figure 11. A two-way ANOVA showed that the effect of temperature was not 
significant (p > 0.05). At 37°C, the unbound fraction of 3H-lopinavir alone or in the 
presence of verapamil or ritonavir did not differ (0.23 ± 0.04, 0.28 ± 0.01, 0.26 ± 0.01, 
respectively). At 4°C, the unbound fraction of 3H-lopinavir alone (0.21 ± 0.01) was 
significantly different from that in the presence of verapamil (0.27 ± 0.03) but was not 
different from that in the presence of ritonavir (0.26 ± 0.03). These results suggest that 
changes in apparent efflux of lopinavir in the presence of ritonavir or at reduced 
temperature are not due to displacement of lopinavir from cellular binding. In addition, 
there was a slight but significant displacement (29%) of lopinavir binding by verapamil at 
4°C. In Figure 9 shown earlier, the trend in the 3H-lopinavir buffer-to-cell ratio in the 
presence of verapamil compared to that in the absence of verapamil at 4°C shows a slight 
increase in apparent efflux of lopinavir, though this increase was not significant. This, in 
addition to minimal displacement by verapamil observed above, indicates a major efflux 
component in lopinavir transport which was inhibited at 4°C (Figure 9). 
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Figure 11: Fraction unbound of 3H-lopinavir (0.32 µM) in the presence or absence of 
verapamil (100 µM) or ritonavir (10 µM) at 37°C and 4°C. Results are presented as mean 
± standard deviation and were analyzed using two-way ANOVA followed by Bonferroni 
post-tests pairwise comparisons. Asterisk indicates significant difference (p < 0.05); other 
comparisons were not significant. 
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Uptake of 3H-lopinavir in BeWo cells: 
Uptake experiments with 3H-lopinavir (0.32 µM) and verapamil (100 µM) were 
carried out. Data were pooled from three separate experiments, each with triplicate 
determinations and the results were expressed as mean ± SEM (% of control). Control 
3H-lopinavir cell/ buffer ratio was 0.107 ± 0.024 (mean ± SD). It is reported that inhibitors 
of ABC transporters like verapamil may also inhibit OATPs (Cvetkovic et al., 1999) and 
thus, may affect the uptake of drugs into the cells. The authors in this study showed that 
verapamil at 100 µM caused a 100% inhibition of OATP-mediated 14C-fexofenadine (2 
µM) uptake. 3H-lopinavir uptake, however, was not sensitive to verapamil (Figure 12). In 
addition, the insensitivity of 3H-lopinavir uptake to reduced temperature suggests the 
involvement of diffusion rather than OATPs. 
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Figure 12: Uptake of 3H-lopinavir (0.32 µM) in the presence or absence of verapamil 
(100µM) at 37°C or 4°C. Data were pooled from three separate uptake experiments, each 
with triplicate determinations and is expressed as Mean ± SEM (% of control). Data were 
analyzed using two-way ANOVA followed by Bonferroni post-tests pairwise comparisons 
(p < 0.05); none of the comparisons were significant. Control (3H-lopinavir cell/ buffer 
ratio) = 0.107 ± 0.024 (mean ± SD). 
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Furthermore, an uptake experiment at 37°C was done with 3H-lopinavir and BSP 
(50 µM) and TC (100 µM) as OATP inhibitors (Figure 13). BSP (50 µM) and TC (100µM) 
inhibit OATP1B1, 1B3 and 1A2 (Fischer et al., 2005). BSP also inhibits OATP2B1 (Sai et 
al., 2006). No significant differences between 3H-lopinavir cell/ buffer ratio between the 
control, BSP treated and TC treated groups were observed. Cis-inhibition with BSP and 
TC as well as trans-stimulation by TC did not change the cell/ buffer ratio compared to 
control, which suggests that the uptake mechanism(s) for 3H-lopinavir in BeWo cells is not 
sensitive to BSP or TC. This indicates that the uptake transporter involved in 3H-lopinavir 
uptake is either an OATP isoform that is not inhibited by BSP or TC or there is an entirely 
different uptake transporter involved. However, temperature independent uptake observed 
in Figure 12 suggests another (unknown) mechanism or simple diffusion. 
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Figure 13: Uptake of 3H-lopinavir (0.32 µM) in the presence or absence of 
bromosulfophthalein (50 µM) or taurocholate (100 µM) at 37°C. Results are presented as 
mean ± standard deviation and were analyzed using one-way ANOVA followed by 
Dunnett’s post-test (p < 0.05); none of the comparisons were significant. 
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CHAPTER 5 CONCLUSIONS 
 
 
Protein binding studies with cord and maternal serum show that fraction unbound 
for lopinavir in serum obtained from cord blood from term placentae of healthy patients 
was 0.022 ± 0.011, which was not significantly different from that observed with maternal 
serum obtained from term placentae (0.0089 ± 0.0012, p= 0.099). Notably, the variances 
were significantly different (p < 0.01), which may imply more variability in unbound 
fraction of lopinavir in cord blood. 
Other protein binding studies show that protein binding of lopinavir is 
characterized by saturable binding to AAG (KD = 5.0 ± 1.1 µM, N = 1.2 ± 0.2) and non-
saturable binding to albumin at physiologic protein concentrations. Although HSA binds 
lopinavir with a somewhat lower affinity (KD = 24.3 ± 8.7 µM, N = 1.1 ± 0.4) and both 
proteins appear to bind lopinavir at a single site, the physiologic concentration of HSA is 
much greater resulting in a much higher binding capacity. As a result, HSA would 
contribute more to the high degree of total plasma protein binding of lopinavir.   
The concentration of serum proteins, the number of binding sites, and the apparent 
KD determine the extent to which drugs such as lopinavir are bound to proteins.  It is 
anticipated that in the absence of active transport processes, equilibrium would occur for 
unbound concentrations in fetal and maternal blood for drugs with a long half-life.  Thus, 
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changes in fraction unbound (due to alterations in binding kinetics) in either circulation 
would change the fetal to maternal serum total drug concentration ratios, while the 
unbound concentration ratios would presumably remain constant. 
Lopinavir binds non-specifically to plastic, BeWo cells, and also to the placental 
tissue. The BeWo cell line is of human origin and expresses various ABC and OATP 
transporters similar to the human placental syncytiotrophoblast. The results suggest that 
verapamil (100µM) stimulated apparent efflux of 3H-lopinavir by two fold, possibly due to 
ABCC2. In addition, this efflux process was 75% inhibited by reduced temperature (4°C). 
Ritonavir (10 µM) also stimulated 3H-lopinavir efflux, whereas GF120918 (1 µM) had no 
effect. Reduced temperature (4°C), verapamil (100 µM) or ritonavir (10 µM) individually 
did not significantly affect the binding of 3H-lopinavir to cell homogenates. However, 
slight but significant binding displacement by verapamil at 4°C was observed. 3H-lopinavir 
uptake was not sensitive to verapamil, BSP, TC or to reduced temperature suggesting 
uptake involves diffusion rather than OATPs. Based on the results obtained with BeWo 
cell culture studies, interplay between cellular binding and ABC efflux transporters, in 
addition to simple diffusion, determines the extent of 3H-lopinavir distribution into BeWo 
cells. 
Further studies considering individual transporters, that is, using a cell line that has 
been transfected by single transporter genes (like MDCK-ABCB1, MDCK-ABCC1) would 
complement studies of lopinavir transport in trophoblasts. Finally, mechanistic studies of 
transplacental transfer of highly protein bound drugs such as lopinavir should consider 
unbound fetal to maternal concentration ratios as well as cellular binding.
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APPENDIX I 
 
IRB APPROVAL AND INFORMED CONSENT FORM 
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APPENDIX II 
 
BeWo CELL CULTURE PROTOCOL 
 
Cell culture medium:  
The medium was prepared by dissolving the contents of one bottle (13.4 g) DMEM 
powdered media in 870 mL of distilled water. It was then supplemented with 3.5g sodium 
bicarbonate, stirred for 20 minutes and pH was adjusted to 7.4 using 1N HCl. 10 mL each 
of 200 mM L-glutamine, 10.000 U/mL penicillin with 10 mg/mL streptomycin and 10 M 
nonessential amino acids were added to the media. This was followed by addition of 10% 
(v/v) FBS and filtering through a 0.22-µm disposable filter in a vertical flow biological 
safety cabinet. The medium was stored at 4°C and was used within 2 weeks. 
 
BeWo cell revival from liquid nitrogen: 
The BeWo cells were grown and cultured according to the protocol previously 
described by Bode et al. (Bode et al., 2006), except for a few minor modifications, which 
are described below in brief: 
1. BeWo cell culture medium (DMEM with 10% FBS) and PBS (1X) were warmed to 
37°C. 10X PBS, pH 7.4 was obtained from Quality Biological Inc., catalog number 
QBI119069101. 
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2. A vial of frozen BeWo cells was removed from a liquid nitrogen storage tank and 
the cells were thawed in a 37°C water bath. 
3. After the cells were thawed, the cell suspension (1.5-2 mL) was immediately 
transferred to a 15 mL falcon tube and 5 mL of cold media (4°C) was added 
dropwise to it. 
4. The cells were centrifuged to pellet at 300 G for 8 minutes at room temperature 
(25°C) using Avanti J-E Centrifuge (Beckman Coulter). 
5. The supernatant was aspirated and the cell pellet was resuspended in 2 mL of 
media. 
6. The entire cell suspension was placed into a 25 cm2 tissue culture flask and another 
6 mL of warm media was added to it. The flask was labeled with the cell line, 
passage number, and date. 
7. The cells were grown in a 37°C incubator supplied with 5% CO2 and 95% relative 
humidity. All procedures were performed with aseptic techniques. 
8. When the cells reached 90-95% confluence, the monolayer was treated with trypsin 
to detach and disperse the cells, as follows. 
9. The media from the 25 cm2 tissue culture flask was aspirated using a sterile Pasteur 
pipet. 
10. The flask was washed with 5 mL of PBS twice in order to remove serum. 
11. The cells were detached from the 25 cm2 flask by incubating them with 5 mL of 1X 
trypsin-EDTA solution (10X trypsin from Invitrogen, catalog number 15400054) in 
PBS for 30 seconds.  
 95
   
12. All but few drops (approximately 1 ml) of the liquid were then aspirated off and the 
flask was placed in the 37°C incubator for approximately 3 minutes. 
13. The 25 cm2 flask was taken out of the incubator and the cell layer examined under 
the microscope to ensure that the cells were detached from the substratum and 
“balled up.” 
14. The cells were then suspended uniformly in 12 mL of media and the entire cell 
suspension was transferred to seed cells in a 75 cm2 tissue culture flask. The flask 
was then labeled with the cell line, passage number, and date. 
15. When the cells became 90-95% confluent, the cells were passaged to a 150 cm2 
tissue culture flask. 
16. The cells were detached and dispersed as described earlier for the cells passaged to 
a 75 cm2 flask, except about 10 mL of the trypsin-EDTA solution was used. 
17. The cells were suspended uniformly in 10 mL of media and 5 mL of such cell 
suspension was seeded into one 150 cm2 tissue culture flask, which already had 20 
mL of media in it. The flask was labeled with the cell line, passage number, and 
date. 
18. Subsequent passages were performed as follows. 
 
BeWo cell passage for cells growing on a 150 cm2 flask: 
1. Media from the flask of cells to be passaged was aspirated and the flask was 
washed with 10 mL of PBS twice. 
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2. The cells were detached and dispersed by incubating them with trypsin-EDTA 
solution (14 mL of 1X trypsin-EDTA in PBS) for 30 seconds. All but few drops of 
the liquid were aspirated off and the flask was placed in the 37°C incubator for 
approximately 3 minutes. The cell detachment was visually confirmed. 
3. 10 mL of the medium was added in the flask to stop trypsinization. The cells were 
uniformly suspended and the entire cell suspension was transferred into a 50 mL 
falcon tube already containing 15 mL of warm media. 
4. The cells were centrifuged to pellet at 300 G for 8 minutes at room temperature 
using Avanti J-E Centrifuge (Beckman Coulter) in JS 5.3 rotor. 
5. The supernatant media was aspirated and the cell pellet was resuspended in 10mL 
of the medium. 
6. 2.5 mL of this cell suspension was seeded to each 150 cm2 tissue culture flask, 
which already had 23 mL of media in it. 
7. One was added to the passage number shown on the initial frozen vial from liquid 
nitrogen. The flask was labeled with the cell line, passage number, and date. 
8. The cells were fed every other day subsequently. 
 
BeWo cell storage: 
1. The cell pellet was obtained from trypsinization of a 150 cm2 flask. 
2. The cells were suspended in 10 mL of DMEM media, the cell density determined 
by using the trypan blue (Sigma Aldrich, catalog number T8154-100mL) exclusion 
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method, and a cell suspension (11 mL) with 1 X 106 cells/mL in DMEM containing 
10% DMSO was created. 
3. 1 mL of cell suspension was transferred to each pre-labeled tissue culture vials 
appropriate for deep freezing. 
4. The cells were frozen by placing in a freezing canister and placing in a -80°C 
freezer for 24 hours. Cell vials were then transferred to a liquid nitrogen storage 
container for long term storage. 
 98
   
 
 
APPENDIX III 
 
LOWRY PROTEIN ASSAY 
 
This assay was based on the method by Lowry et al. (Lowry et al., 1951). 
1. Solutions A (2% Na2CO3 in 0.1 N NaOH), B1 (1% CuSO4.5H2O in H2O), and B2 
(2% KNa tartarate in H2O) were mixed in the proportion A = 98 mL, B1 = 1 mL, 
and B2 = 1mL. This was called Reagent 1. 
2. Bovine serum albumin, fraction V (BSA) was added as the standard at volumes 0, 
5, 10, 20, 40, 60, 80 µL. 20 µL PBS was added to each and the total volume was 
brought to 500µL. 
3. Samples: To 2.5, 5, 10 µL of the samples (cell or tissue homogenates), 20 µL of 
PBS was added, followed by 480 µL of water. 
4. 2.5 mL of reagent 1 was added to each tube and was vortexed each time. 
5. This was let stand at room temperature for 10 minutes. 
6. 250 µL of 1N Folin Ciocolteu’s reagent (2N solution was diluted 1:1 with water) 
was added to each tube and vortexed each time. 
7. The samples were let stand at room temperature for 30 minutes before reading at 
660 nm in a spectrophotometer. 
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APPENDIX IV 
 
RESULTS OF THE PRELIMINARY EXPERIMENTS PERFORMED 
WITH 3H-LOPINAVIR USING BeWo CELL LINE 
 
Preliminary uptake and efflux experiments on standard cell culture plates were 
carried out with 3H-lopinavir (0.32 µM) and different inhibitors of ABC transporters 
present on the maternal side of the placental syncytiotrophoblast. 
There were some technical issues that came up and thus, hindered interpretation of 
results. The experiments with the results below had one or more of the following issues: 
1. Cells were not washed with ice-cold buffer before adding the lysis buffer in an 
uptake experiment. 
2. In an efflux experiment, cells were not washed with ice-cold buffer after aspirating 
the uptake buffer and before adding the efflux buffer. They were also not washed 
before adding the lysis buffer. 
3. Stock buffers were not analyzed 
4. Samples from stock solutions of 3H-lopinavir ± verapamil were not counted in 
triplicate, so as to account for the difference in 3H-lopinavir in the two stocks 
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An uptake experiment with BeWo cells grown on 12-well plates was done with 3H-
lopinavir (0.32 µM). Verapamil (100 µM) was used as an ABCB1 inhibitor. A 
significantly lower 3H-lopinavir cell/buffer ratio was observed in the presence of verapamil 
at 10 minutes (Figure 14). The results suggested that uptake of 3H-lopinavir was inhibited 
in the presence of verapamil. This was not consistent with ABC transporters but suggested 
an involvement of uptake transporters. 
 
Figure 14: Uptake of 3H-lopinavir (0.32 µM) in the presence or absence of verapamil 
(100µM). Results are presented as mean ± standard deviation and were analyzed using 
two-way ANOVA followed by Bonferroni post-tests pairwise comparisons. Asterisks 
indicate significant difference (p < 0.05); other comparisons were not significant. 
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The above experiment was repeated with two washing steps before adding the lysis 
buffer (Figure 15). A significantly lower 3H-lopinavir cell/buffer ratio was again observed 
in the presence of verapamil, at all time intervals studied. Verapamil inhibited apparent 
3H-lopinavir uptake by ~30% in 10 minutes. The results were consistent with inhibition of 
uptake transporters or stimulation of ABC transporters, and inconsistent with inhibition of 
ABC transporters, as originally expected. 
 
Figure 15: Uptake of 3H-lopinavir (0.32 µM) in the presence or absence of verapamil 
(100µM). Results are presented as mean ± standard deviation and were analyzed using 
two-way ANOVA followed by Bonferroni post-tests pairwise comparisons. Asterisks 
indicate significant difference (p < 0.05); other comparisons were not significant. 
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An efflux experiment done with 3H-lopinavir and verapamil showed a significantly 
higher buffer/cell ratio in the presence of verapamil at 5, 10, and 20 minutes (Figure 17). 
Lopinavir efflux was linear with time to 20 minutes and the efflux rate (slope) was 
increased by verapamil. The results again indicated an inhibition of uptake by verapamil or 
a possible stimulation of efflux by verapamil. 
 
Figure 16: Efflux of 3H-lopinavir (0.32 µM) in the presence or absence of verapamil 
(100µM). Results are presented as mean ± standard deviation and were analyzed using 
two-way ANOVA followed by Bonferroni post-tests pairwise comparisons. Asterisks 
indicate significant difference (p < 0.05); other comparisons were not significant. 
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An efflux experiment was also done with 3H-lopinavir and sodium orthovanadate 
(500 µM) as an inhibitor of all ATP-dependent processes (Figure 18). A significantly 
higher 3H-lopinavir buffer/cell ratio was observed in the presence of sodium 
orthovanadate, which indicated an increase in 3H-lopinavir efflux in the presence of 
sodium orthovanadate. The cells were, however, not washed before adding the lysis buffer 
and the results were, therefore, again inconclusive. 
 
Figure 17: Efflux of 3H-lopinavir (0.32 µM) in the presence or absence of sodium 
orthovanadate (500µM). Results are presented as mean ± standard deviation and were 
analyzed using two-way ANOVA followed by Bonferroni post-tests pairwise comparisons. 
Asterisks indicate significant difference (p < 0.05); other comparisons were not significant. 
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Triplicate samples from the stock solutions of 3H-lopinavir ± sodium orthovanadate 
in the above experiment were counted and the results indicated that there was a significant 
difference between 3H-lopinavir present in the two stocks; the stock with sodium 
orthovanadate having 3-times higher 3H-lopinavir concentration compared to the stock 
without sodium orthovanadate. 
An efflux experiment was carried out with a pre-incubation step in the presence of 
0.05 % BSA so that BSA occupies the non-specific binding sites and a better estimate of 
lopinavir transport can be determined. A significantly higher 3H-lopinavir buffer/cell ratio 
was observed in the presence of verapamil at 5, 10, 15 and 20 minutes (Figure 19). This 
again showed that verapamil either inhibited 3H-lopinavir uptake or stimulated its efflux. 
Figure 18: Efflux of 3H-lopinavir (0.32 µM) in the presence or absence of verapamil 
(100µM). Results are presented as mean ± standard deviation and were analyzed using 
two-way ANOVA followed by Bonferroni post-tests pairwise comparisons. Asterisks 
indicate significant difference (p < 0.05). 
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Verapamil may also inhibit a bi-directional uptake transporter present on the apical 
side of the BeWo cells. Because verapamil was observed to displace 3H-lopinavir from 
non-specific binding sites, a possibility of it displacing 3H-lopinavir from intracellular 
binding sites and resulting in an increase in unbound 3H-lopinavir fraction in the cells and 
therefore, causing an increase in efflux cannot be ruled out. To further solve this puzzle, it 
was necessary to differentiate between the uptake and efflux processes by not including 
verapamil at the uptake step in the efflux experiments, in contrast to the previous 
experiments where verapamil was present at the uptake step in the efflux experiments. 
 
Experiments to differentiate between uptake and binding: 
To differentiate between binding and uptake issues, further uptake and efflux 
experiments were carried out at 37°C and at a lower temperature (4°C), assuming that the 
transport processes at 4°C would be inhibited and therefore, would help to differentiate 
between uptake and binding processes. The experiments were carried out as mentioned 
above, but at two temperatures with control and verapamil treated group. There were a few 
issues that came up with the initial experiments and those results are shown in Figures 
19-21 and discussed below: 
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Figure 19: Uptake experiment with 3H-lopinavir (0.32 µM) and verapamil (100 µM) at 
37°C and 4°C. Results are presented as mean ± standard deviation and were analyzed using 
two-way ANOVA followed by Bonferroni post-tests pairwise comparisons. Asterisks 
indicate significant difference (p < 0.05); “ns” indicates that the comparison was not 
significant. 
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There was no washing done with ice-cold buffer (4°C) before adding the lysis buffer. 
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Figure 20: Uptake experiment with 3H-lopinavir (0.32 µM) and verapamil (100 µM) at 
37°C and 4°C. Results are presented as mean ± standard deviation and were analyzed using 
two-way ANOVA followed by Bonferroni post-tests pairwise comparisons. Asterisks 
indicate significant difference (p < 0.05); “ns” indicates that the comparison was not 
significant. 
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The uptake step at 4°C was not exactly 10 minutes. 
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Figure 21: Efflux experiment with 3H-lopinavir (0.32 µM) and verapamil (100 µM). 
Results are presented as mean ± standard deviation and were analyzed using two-way 
ANOVA followed by Bonferroni post-tests pairwise comparisons. Asterisks indicate 
significant difference (p < 0.05); “ns” indicates that the comparison was not significant. 
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Washing was done with buffer at 37°C for the experiment at 37°C. Also, the uptake step at 
4°C for 10 minutes was actually at 37°C for 5 minutes and at 4°C for further 5 minutes. 
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